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SAPK     stress-activated protein kinase 
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1. INTRODUCTION 
1.1 Proto-oncogene c-jun and JNK signaling pathway 
The nuclear proto-oncogene c-jun encodes a major component of the AP-1 
(activator protein-1) transcription factor family comprising the Jun (c-Jun, JunB, JunD), 
Fos (c-Fos, Fra-1, Fra-2, FosB) and CREB/ATF (ATF-2, ATF-3) proteins.1,2 AP-1 
transcription factors belong to the bZIP superfamily of proteins, which dimerize and bind 
DNA via the basic domain/leucine zipper region, respectively.3-5 Dimerization is a 
prerequisite for binding to the DNA consensus site in target gene promoters and thus for 
transcriptional activity.3,6 
c-Jun homodimerizes or heterodimerizes with other AP-1 family members and 
dependent on the heterodimerizing partner, c-Jun recognizes either TPA or cAMP response 
elements in promoters.7-9 TPA response elements are phorbol ester and growth factor 
inducible and preferentially bind c-Jun homodimers or c-Jun/c-Fos heterodimers. cAMP 
response elements (CRE) preferentially bind ATF/CREB family members or ATF-2/c-Jun 
heterodimers.10 
Interestingly, the promoter region of the c-jun gene itself contains two variant         
AP-1/CRE binding sites, a proximal and a distal site, which are important for basal 
promoter activity.11 The more proximal AP-1 site differs from the AP-1 site in the 
collagenase promoter by a nucleotide insertion (underlined) and has the sequence:            
5’-TGACATCA-3’. The distal AP-1 site differs from the AP-1 site in the SV40 enhancer 
by an additional base pair (underlined): 5’-TTACCTCA-3’.11 c-Jun preferentially 
heterodimerizes with ATF-2 at these two AP-1/CRE sites.12-14 The more proximal          
AP-1/CRE (pAP-1) site is the main site at which c-Jun stimulates its own transcription in a 
positive autoregulatory loop.15,16  
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For transcriptional and autoregulatory activity, c-Jun requires phosphorylation by 
the Jun NH2-terminal kinase (JNK).17-19 JNK belongs together with p38 and ERK to the 
mitogen activated protein (MAP) kinase family. MAP kinases (MAPK) are phosphorylated 
on threonine and tyrosine residues by dual-specificity MAPK kinases, which are 
themselves activated by MAPK kinase kinases.20 JNK interacts with c-Jun via a small 
region (delta domain) within the NH2-terminal activation domain19,21 and phosphorylates 
Serine 63 (Ser63) and Serine 73 (Ser73) in c-Jun, which increases the transactivation 
potential of c-Jun.17,18  After phosphorylation, inactive JNK remains bound to c-Jun and 
mediates degradation of c-Jun by ubiquitination.22  
c-Jun is an environmental sensor and the JNK signaling pathway connects c-Jun to a 
variety of extracellular factors, such as UV irradiation,12,23  growth factors24 and 
cytokines.25-27 Thus, c-Jun and JNK regulate crucial physiological processes like 
proliferation, apoptosis or differentiation. Functional properties of c-Jun and JNK vary 
dependent on the cell type and cell stage, the incoming signals and also the dimer 
composition.28,29 
c-Jun is, however, also located at the end of signaling cascades that include 
important oncogenes active in human tumors.1,13,30 Oncogenes like Ha-ras,31 cot32 and met33 
require phosphorylation of Ser63 and Ser73 in c-Jun by JNK for their transformation 
capacities. c-Jun alone is, in contrast to its viral counterpart v-Jun, a relatively weak inducer 
to transformation.34 It has been described that N-terminal phosphorylation of Ser63 and 
Ser73, located in the transactivation domain of c-Jun, augments c-Jun mediated 
transformation.35,36 This is further indicated in transgenic mice, which express a dominant 
negative form of c-Jun lacking the transactivation domain including the Ser63 and Ser73 
phosphorylation sites. These mice are protected against skin tumor promotion.37  
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Furthermore, overexpression of c-Jun has been associated with transformation and 
tumor promotion. Overexpression of c-Jun can result from sustained JNK phosphorylation, 
which prevents degradation of c-Jun by ubiquitination.38,39 Overexpression of c-Jun and 
constitutive activation of JNK have therefore been associated with a variety of solid 
cancers.40-42 Generally, reversion of highly tumorigenic cell lines to a non-tumorigenic 
phenotype is associated with c-Jun downexpression.43  
In addition, overexpression of c-Jun and sustained JNK activation has been shown 
to play an important role in leukemic cells with translocations. Chronic myeloid leukemia 
(CML) cells with the translocations t(9;22) or t(3;21) show elevated AP-1 activity, which 
has been associated with the leukemic transformation process.44-47 Studies on t(9;22) have 
further revealed that the resulting BCR-ABL fusion gene constitutively activates the JNK 
signaling pathway and increases c-Jun expression in BCR-ABL positive patient cells.48  
There are indications that enhanced AP-1 activity might also play a role in 
translocations associated with acute myeloid leukemia (AML). Overexpression of the 
AML1-ETO fusion gene, resulting from the translocation t(8;21), in fibroblast cells, results 
in transformation and has been associated with increased levels of phosphorylated Ser63 in 
c-Jun and enhanced AP-1 activity.49 The pathophysiological importance of these findings, 
however, has not been confirmed in primary leukemia patient samples on the basis of 
increased levels of c-Jun expression.  
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1.2 Acute myeloid leukemia and translocation t(8;21) 
Acute myeloid leukemia (AML) accounts for about 1-1.5% of all cancers in 
Western countries.50 AML is a clonal disorder resulting from an acquired somatic mutation 
in hematopoietic progenitor cells and is characterized by an accumulation of immature 
myeloid cells in the bone marrow, which are arrested in maturation. Frequently in AML, 
the acquired mutation is the consequence of a balanced reciprocal chromosomal 
translocation, which disrupts genes residing in the breakpoint regions of the translocation 
by generating fusion genes.51,52 The genes located at these breakpoints often encode 
transcription factors which are master regulators of hematopoietic cell differentiation, 
apoptosis or proliferation.53  
Despite the heterogeneity of AML, the identification of recurring chromosomal 
rearrangements and the resulting molecular abnormalities have identified distinct subgroups 
of patients with predictable clinical features and therapeutic responses.54 The most frequent 
cytogenetic abnormalities in AML, accounting for approximately 40% of all AMLs, are the 
translocations t(8;21), t(15;17), inv(16) or t(9;11), encoding for the AML1-ETO,         
PML-RARa, CBFß-SMMHC or MLL-AF9 fusion proteins, respectively.51  
AML1-ETO is associated with approximately 40% of AML cases with the M2 
subtype according to the French-American-British (FAB) classification and represents one 
of the most frequent chromosomal translocation in AML (18-20%).51 t(8;21) is a balanced 
translocation between chromosomes 8 and 21 resulting at the molecular level in the fusion 
of the AML1 gene normally located on chromosome 21q22 with the ETO                       
(Eight-Twenty-One) gene on chromosome 8q22.55,56 
The wildtype AML1 gene encodes for the CBFa2 protein, which is a physiological 
component of the core binding factor (CBF) family.57 AML1 appears to function as a 
transcriptional organizer necessary for the development of definitive hematopoietic stem 
cells.58 In fact, CBF null mice die in utero in the absence of terminal hematopoietic 
differentiation.59-61  
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Transcriptional function of AML1 is mediated through the core enhancer DNA 
sequence present in promoters and enhancers of a large number of hematopoietic specific 
genes.62 AML1 binds this sequence through the runt homology domain and its DNA 
binding affinity is increased by heterodimerization with CBFb.63 Finally, AML1 has been 
shown to co-operate with other basic transcription factors in activating a set of 
hematopoietic specific genes.64 
ETO was unknown prior to its identification as the fusion partner of AML1 in 
t(8;21).55,65,66 ETO is expressed as a nuclear phosphoprotein in brain and in CD34+ 
hematopoietic cells.67,68 It contains four evolutionarily conserved regions, the so-called 
nervy homology regions (NHR) 1-4, which have been shown to make several contacts with       
co-repressors and histone deacetylases.69 Although ETO is a nuclear zinc-finger containing 
protein and thus might function as a transcriptional regulator, there is no experimental 
evidence to suggest that it can directly bind to DNA.  
In the translocation t(8;21), the DNA binding domain (runt domain) of AML1 is 
fused to nearly the complete ETO gene yielding a protein of 752 amino acids.55,65,70 Several 
important regions of AML1 are lost, like the C-terminal transactivation domain, interaction 
sites for TLE and sin3 co-repressors, the nuclear targeting signal and a MAPK 
phosphorylation site.71 AML1-ETO sequesters the co-activator CBFb from wildtype AML1 
by binding CBFb through the retained runt domain more efficiently.72 Thus, AML1-ETO 
can bind to AML1 target genes instead of wildtype AML1,62 and dominantly represses 
transcription of AML1 target genes by permanently tethering a repressor complex to AML1 
responsive promoters through ETO.73-76 The importance of disruption of wildtype AML1 
by AML1-ETO is shown by a similar phenotype in AML1 knock-out and AML1-ETO 
knock-in studies.77,78 
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AML1-ETO blocks the transactivation of wildtype AML1 target genes important for 
myeloid differentiation, like the TCRb reporter, the GM-CSF promoter, c-fos,79 Art-1,80 or 
the TGFb signaling pathway.81 Furthermore, AML1-ETO disrupts the protein-protein 
interactions of AML1 with important myeloid transcription factors like C/EBPa82,83 or 
MEF-2,84 and also represses transactivation through those transcription factors. Therefore, 
AML1-ETO might be responsible for the differentiation arrest in t(8;21). Along with that, 
several cellular and murine model systems have documented the ability of AML1-ETO to 
inhibit myeloid differentiation.45,85-88 
It has recently been shown that AML1-ETO might also be responsible for the gain 
of function properties characterizing leukemogenesis. Expression of AML1-ETO in 
primary human CD34+ stem cells, the target cell affected in AML, results in a proliferative 
and survival advantage of leukemic cells, which promotes their expansion.89 Introduction of 
the AML1-ETO cDNA into the AML1 locus by homologous recombination leads to 
embryonic lethality in heterozygous animals.77,78  Culturing the yolk sac cells of these mice, 
however, yields dysplastic monocytic colonies.77 In a similar AML1-ETO knock-in mouse 
study, aberrant myelomonocytic colonies are derived from fetal liver.78 Therefore, despite 
the fact that AML-ETO alone has not been shown to cause leukemia,90,91 these studies 
indicate that AML1-ETO encourages uncontrolled cell growth and might predispose to 
leukemia.  
Along with that, several positively regulated target genes of AML1-ETO have been 
described. AML1-ETO has been reported to activate the macrophage-colony stimulating 
factor (M-CSF) receptor promoter in co-operation with wildtype AML1 via the core 
enhancer consensus site. It is proposed that AML1-ETO enhances the transactivation 
potential of wildtype AML1 by sequestering AML1 bound corepressors.92  
Furthermore, AML1-ETO has been shown to transactivate the BCL-2 promoter via 
the AML1 consensus site in AML1-ETO expressing Kasumi-1 cells.93 The physiological 
relevance of these findings is, however, doubtful, since in primary t(8;21) positive patient 
cells, BCL-2 expression is lower than in other forms of leukemia.94,95  
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It has recently been shown that expression levels of the granulocyte-colony stimulating 
factor (G-CSF) receptor are increased in AML1-ETO containing cell lines and in fresh 
t(8;21) positive leukemic cells.96 The data indicates that AML1-ETO induces the 
expression of the G-CSF receptor promoter in an indirect manner by increasing the 
expression of C/EBPe , which transactivates the G-CSF receptor promoter.96  
Interestingly, a differential display analysis using AML1-ETO expressing cells has 
revealed a surprising number of genes that are increased in their expression levels, but are 
not target genes of AML1.97  
Only few of these positively regulated target genes of AML1-ETO have been 
confirmed in primary t(8;21) positive cells. Furthermore, the molecular mechanisms behind 
the gain of function properties of AML1-ETO remain largely unknown. 
2. Aim of the Study  8 
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2. AIM OF THE STUDY 
· Based on the role of c-Jun and the JNK signaling pathway in the transformation process 
of chromosomal translocations associated with CML, we hypothezised that c-Jun might 
also play a role in reciprocal chromosomal translocations in AML.  
What are the expression levels of c-jun in primary AML patient cells with the most 
common AML-associated cytogenetic abnormalities: t(8;21), t(15;17), inv(16) or 
t(11q23/MLL)? 
· It has previously been described that overexpression of AML1-ETO in fibroblast cells 
results in an increase in phosphorylated Ser63 in c-Jun, which has been implicated in 
the transformation process.49 Phosphorylated c-Jun can autoregulate its expression.15,16 
Are the expression levels of c-jun enhanced in primary t(8;21) positive patient cells 
and myeloid cell lines? 
Is c-jun a direct target of AML1-ETO and what is the role of the JNK signaling 
pathway, which can phosphorylate Ser63 in c-Jun, in myeloid cells? 
Is the JNK signaling pathway of importance for the functional and biological 
properties of t(8;21) positive AML? 
· AML1-ETO has no known kinase activity. It is currently unknown how AML1-ETO 
enhances the phosphorylation of a protein. 
What might be the underlying molecular mechanism of AML1-ETO influencing a 
signaling pathway? 
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3. MATERIALS 
3.1 Cell lines 
U937 
Human histiocytic lymphoma. Source: ACC5, DSMZ, Braunschweig, Germany 
U937 WITH ZINC-INDUCIBLE EXPRESSION OF AML1-ETO (U937Z/A-E) 
Source: Pier Giuseppe Pelicci, Instituto Europeo di Oncologia, Milano 
U937 WITH TET-REGULATED EXPRESSION OF AML1-ETO (U937T/A-E) 
Source: Dong-Er Zhang, The Scripps Research Institute, La Jolla88 
U937 TET (U937T)  
Control cell line containing the tetracycline-responsive transcriptional repressor 
tTA. Source: Dong-Er Zhang, The Scripps Research Institute, La Jolla88 
KASUMI-1 
Human acute myeloid leukemia. Source: ACC220, DSMZ, Braunschweig, 
Germany 
293T 
Human embryonal kidney. Source: ACC305, DSMZ, Braunschweig, Germany 
3.2 Patient material 
Patient samples were referred to the Laboratory for Leukemia Diagnostics, 
Department of Medicine III, Klinikum Großhadern, Munich, for routine cytogenetic and 
cytomorphologic analyses. All samples were from the time of diagnosis. AML patient 
samples analyzed by microarray analysis had only a single translocation, the group of 
t(11q23/MLL) positive patient samples contained one sample with a t(11;19), one sample 
with a t(6;11), one with a t(11;22) and seven samples with a t(9;11).  
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In the t(8;21) positive patient samples analyzed by real-time PCR, thirteen patients 
had an AML FAB subtype M2 and in three cases the AML FAB subtype had not been 
analyzed (patient numbers 8, 10 and 15, Figure 2). Three patients had a t(8;21) as sole 
cytogenetic abnormality (patient numbers 7, 11 and 16, Figure 2), thirteen had loss of a sex 
chromosome, two had trisomy 8 (patient numbers 2 and 10, Figure 2) and one a t(15;20) 
(patient number 10, Figure 2). The AML1-ETO transcript was observed in all cases (patient 
numbers 1 to 16, Figure 2).  
3.3 Plasmids, reporter constructs, primers, 
oligonucleotides 
PLASMIDS 
pcDNA3.1 
Eukaryotic expression vector. Source: Invitrogen, Groningen, The Netherlands 
pCMV5 
Eukaryotic expression vector, 4.7Kb, with ampicillin resistance gene and strong 
CMV promoter. Source: Amersham Pharmacia, Freiburg, Germany 
pRL-null 
Control reporter vector for the Dual-luciferase reporter assay system containing 
the cDNA encoding Renilla luciferase without eukaryotic promoter and/or 
enhancer elements. Source: Promega, Madison, WI, USA 
pGdBBX 
 Full-length G6PD cDNA in the expression vector pUC12. 
Source: Andreas Hochhaus, III. Medizinische Universitätsklinik, Mannheim, 
Germany98 
Human pCMV5 AML1-ETO 
Source: Scott Hiebert, St. Jude Children’s Hospital, Memphis, USA 
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Human pCMV5 ETO 
(S. Hiebert) 
Human pCMV5 CBFß 
(S. Hiebert) 
Human pCMV5 AML1 
 (S. Hiebert) 
Murine pSV-SPORT1 c-jun 
Source: Trang Hoang, Clinical Research Institute of Montreal, QC, Canada 
Human pCMV5 JIP-1 
Source: Roger Davis, Howard Hughes Medical Institute, Massachusetts, USA 
Murine pSP65 c-jun 
c-jun for in vitro translation using SP6 polymerase. Source: Elisabetta Mueller 
and Bruce Spiegelman, Dana Farber Cancer Institute, Boston, MA99  
REPORTER CONSTRUCTS 
Human c-jun promoter [bp -1780 to bp +731] in pGL3  
Source: Wayne Vedeckis, State University Medical Center, New Orleans, USA 
Human c-jun promoter [bp -952 to bp +731] in pGL3  (W. Vedeckis) 
Human c-jun promoter [bp -719 to bp +731] in pGL3  (W. Vedeckis) 
Human c-jun promoter [bp -345 to bp +731] in pGL3  (W. Vedeckis) 
Human c-jun promoter [bp -180 to bp +731] in pGL3  (W. Vedeckis) 
Human c-jun promoter [bp -63 to bp +731] in pGL3  (W. Vedeckis) 
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Human c-jun promoter [bp -79 to bp +170] in pGL2  
Source: Xiao-Fan Wang, Duke University Medical Center, Durham, North 
Carolina, USA 
Human c-jun promoter [bp -79 to bp +170] in pGL2 with the proximal AP-1 site: 
5’-tg aca tca-3’ mutated to 5’-at cca cca-3’ (X.-F. Wang) 
Minimal c-fos promoter element containing 3x NF-?B binding sites in pGL2 
Source: Marius Ueffing, Institute of Human Genetics, GSF, Munich, Germany 
Minimal c-fos promoter element containing 3x mutated NF-?B binding sites in 
pGL2 (Marius Ueffing) 
Human M-CSF receptor promoter [bp -416 to bp +71] in pXP2 
Source: D.E. Zhang, Scripps Research Institute, La Jolla, CA, USA92 
pGL2, pGL3 
 Luciferase reporter gene vectors. Source: Promega, Mannheim, Germany 
pXP2 
Luciferase reporter gene vector. Source: Stephen Nordeen, Department of 
Pathology, University of Colorado, Denver, USA 
PRIMERS 
c-jun Sense: 5’-gca tga gga acc gca tcg ctg cct cca agt-3’100 
c-jun Antisense: 5’-gcg acc aag tcc ttc cca ctc gtg cac act-3’100 
G6PD Sense: 5’-ccg gat cga cca cta cct ggg caa g-3’98 
G6PD Antisense: 5’-gtt ccc cac gta ctg gcc cag gac ca-3’98 
AML1-ETO Sense: 5’-atg acc tca ggt ttg tcg gtc g-3’ 
AML1-ETO Antisense: 5’-tga act ggt tct tgg agc ctc ct-3’ 
G-CSF receptor Sense: 5’-cct gga gct gag aac tac cg-3’101 
G-CSF receptor Antisense: 5’-tcc cgg ctg agt tat agg-3’101 
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G-CSF Sense: 5’-gct tga gcc aac tcc ata gc-3’ 
G-CSF Antisense: 5’-aaa tgc agg gaa gga cac ag-3’ 
pcjun -63/+170 Sense: : 5’-tgg gct att ttt agg ggt tga ctg g-3’ 
pcjun -63/+170 Antisense: 5’-agc cac agg cgc tag ctc tgg g-3’ 
OLIGONUCLEOTIDES FOR EMSA 
Human c-jun promoter [bp -88 to bp -28] 
5’-tgg gaa ggc ctt ggg gtg aca tca tgg gct att ttt agg ggt tga ctg gta gca gat aag-3’ 
Human c-jun promoter [bp -88 to bp -28] with mutated proximal AP-1 site 
5’-tgg gaa ggc ctt ggg gat cca cca tgg gct att ttt agg ggt tga ctg gta gca gat aag-3’ 
AML1 consensus site 62 
5’-aat tcg agt att gtg gtt aat acg-3’ 
3.4 Antibodies, peptides 
ANTIBODIES 
anti c-Jun/AP-1 (N) 
Polyclonal rabbit antibody against the amino terminal domain of c-Jun. Dilution for 
Western blot: 1:1,000. Used also in EMSA (200µg/0.1ml). Source: Santa Cruz 
Biotechnology, Santa Cruz, CA 
anti ETO (C-20)  
Polyclonal goat antibody against the carboxy terminus of ETO. Dilution for 
Western blot: 1:1,000. Used also in EMSA (200µg/0.1ml). Source: Santa Cruz 
anti b-tubulin (H-235)  
Polyclonal rabbit antibody against amino acids 210-444 at the carboxy terminus of 
b-tubulin. Dilution: 1:500. Source: Santa Cruz 
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anti JNK1 (C-17)  
Polyclonal rabbit antibody against the carboxy terminus of JNK1. Dilution: 1:1,000. 
Source: Santa Cruz 
anti AML1 (N-20)  
Polyclonal goat antibody against the amino terminus of AML1. Used in EMSA 
(200µg/0.1ml). Source: Santa Cruz 
anti c-fos (4)  
Polyclonal rabbit antibody against the amino terminus of c-fos. No cross-reactivity 
to Fos B, Fra-1 or Fra-2. Used in EMSA (200µg/0.1ml). Source: Santa Cruz 
anti ATF-2 (F2BR-1)  
Mouse monoclonal antibody against amino acids 350-505 within the DNA binding 
and dimerization domain of ATF-2. Used in EMSA (200µg/0.1ml).                
Source: Santa Cruz 
anti GST (Z-5) 
Rabbit polyclonal antibody against GST fusion proteins. Dilution: 1:1,000.      
Source: Santa Cruz 
normal IgG rabbit  
Isotype control for rabbit antibodies. Source: Santa Cruz 
normal IgG goat 
Isotype control for goat antibodies. Source: Santa Cruz 
anti phosphorylated Thr183/Tyr185 in SAPK/JNK  
Polyclonal rabbit antibody. Detects SAPK/JNK only when activated by 
phosphorylation at Thr183/Tyr185. Dilution: 1:1,000. Source: New England 
Biolabs, Schwalbach, Germany 
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anti phosphorylated Thr71 in ATF-2  
Polyclonal rabbit antibody. Recognizes ATF-2 only when phosphorylated at Thr71. 
Dilution: 1:1,000. Source: New England Biolabs 
anti phosphorylated Ser63 in c-Jun 
Polyclonal rabbit antibody, detects phosphorylated Ser63 in c-Jun, but does not 
cross-react with the corresponding phosphorylated forms of JunD or JunB.    
Dilution: 1:1,000. Source: New England Biolabs 
anti phosphorylated Ser73 in c-Jun 
Polyclonal rabbit antibody, detects phosphorylated Ser73 in c-Jun and Ser100 in 
JunD, but does not cross-react with up to 0.5µg of nonphosphorylated c-Jun or 
JunD. Dilution: 1:1,000. Source: New England Biolabs 
donkey anti rabbit IgG (NA934)  
HRP-conjugated secondary antibody. Dilution: 1:2,000. Source: Amersham 
Pharmacia, Freiburg, Germany 
rabbit anti goat (P0449)  
HRP-conjugated secondary antibody. Dilution: 1:2,000. Source: DAKO, Denmark 
PEPTIDES 
JNK inhibitor I (L)-form 
A cell permeable, biologically active peptide that diminishes JNK signaling 
pathway by blocking the activation of transcription factor c-Jun. 20 amino acids of 
the islet-brain-1 protein, an isoform of JIP-1, inhibiting JNK induced 
phosphorylation of c-Jun by interacting in the JNK binding domain (delta domain) 
of c-Jun, are fused to 10 amino acids of a HIV-TAT carrier, which rapidly 
translocates into the cells. Source: Calbiochem, Darmstadt, Germany102 
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HIV-TAT 48-57, Negative control 
A highly cell-permeable 10-amino acid carrier peptide derived from HIV-TAT     
48-57 sequence that is modified with two proline residues. Source: Calbiochem, 
Darmstadt, Germany102 
3.5 Laboratory materials 
CHEMICALS 
Acrylamide/Bisacrylamide 40% (Serva, Heidelberg, Germany) 
Agarose (Serva, Heidelberg, Germany) 
Ammonium peroxidisulfate (APS) (Bio-rad, Munich, Germany) 
[g-32P]ATP (3000Ci/mmol at 10mCi/ml) (Amersham Pharmacia, Freiburg, Germany) 
Bio-rad Protein estimation kit (Bio-rad, Munich, Germany) 
Detection system ECL® (Amersham Pharmacia, Freiburg, Germany) 
DNA molecular weight markers (Roche Diagnostics, Mannheim, Germany) 
dNTPs (Promega, Mannheim, Germany) 
Dual-luciferase reporter assay system (Promega, Mannheim, Germany) 
Dulbeccos modified Eagle medium (DMEM) (PAN, Aidenbach, Germany) 
Effectene® transfection kit (Qiagen, Hilden, Germany) 
Ethidium bromide (Life Technologies, Karlsruhe, Germany) 
Fast Start DNA SYBR Green I kit (Roche Diagnostics, Mannheim, Germany) 
Genzyme TACSTM AnnexinV kit (R&D systems, Wiesbaden, Germany) 
Granocyte® 34: Human recombinant G-CSF (Chugai, Frankfurt, Germany) 
L-Glutamine (Life Technologies, Karlsruhe, Germany) 
Liquid nitrogen (Linde, Munich, Germany) 
Maxiprep® DNA isolation kit (Qiagen, Hilden, Germany) 
Onmiscript® RT cDNA synthesis kit (Qiagen, Hilden, Germany) 
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PBS (PAN, Aidenbach, Germany) 
PCR primers, oligo dT (Metabion, Martinsried, Germany) 
Penicillin-Streptomycin (Life Technologies, Karlsruhe, Germany) 
poly(dI-dC) (Amersham Pharmacia, Freiburg, Germany) 
Protein markers (Amersham Pharmacia, Freiburg, Germany) 
Restriction enzymes (New England Biolabs, Schwalbach, Germany) 
RNasin® RNase inhibitor (Promega, Mannheim, Germany) 
RNeasy® RNA isolation kit (Qiagen, Hilden, Germany) 
RPMI 1640 medium (PAN, Aidenbach, Germany) 
SAPK/JNK assay kit (Cell signaling technology, Beverly, USA) 
SDS (Bio-rad, Munich, Germany) 
T4 polynucleotide kinase (New England Biolabs, Schwalbach, Germany) 
Taq polymerase (Qiagen, Hilden, Germany) 
TnT® reticulocyte lysate system (Promega, Mannheim, Germany) 
TOPO TA PCR2.1 (Invitrogen, Groningen, The Netherlands) 
Tran 35S-labelT M (>1000Ci/mmol at 10mCi/ml) (ICN Biomedicals, Eschwege, Germany) 
Tris (Bio-rad, Munich, Germany)  
Trypan blue 0.5% (Serva, Heidelberg, Germany) 
Trypsin (PAN, Aidenbach, Germany) 
All the other chemicals were obtained from Sigma (St. Louis, USA). 
LABORATORY EQUIPMENT, CONSUMABLES 
Incubator for bacteria (Heraus, Hanau, Germany) 
Shaker for bacteria (New Brunswick Scientific, Nürtingen, Germany) 
Blotting paper (Schleicher& Schüll, Dassel, Germany) 
ECL® films (Amersham Pharmacia, Freiburg, Germany) 
Eppendorf® tabletop centrifuge 5415D (Eppendorf, Hamburg, Germany) 
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Developing machine (Agfa-gevaert, Leverkusen, Germany) 
Gel electrophoresis systems (Bio-rad, Munich, Germany; OWL, Portsmouth, USA) 
Heating block (Techne, Cambridge, UK) 
ImmobilonT M-P transfer membranes (Millipore, Bedford, Massachusetts, USA) 
Parafilm M® (American National Can, Greenwich, USA) 
Thermal cycler (Perkin Elmer, Norwalk, USA) 
Light CyclerT M real-time PCR machine (Roche Diagnostics, Mannheim, Germany) 
Luminometer Turner Designs TD-20/20 (Promega, Madison, WI, USA) 
pH-meter (WTW, Weilheim, Germany) 
Photometer (Amersham Pharmacia, Freiburg, Germany) 
Pipettes (Gilson, Langenfeld, Germany) 
Pipette tips (Star Labs, K&K Laborbedarf, Munich, Germany) 
QuickSpin® columns (Roche Diagnostics, Mannheim, Germany) 
Freezing vials (Nunc, Roskilde, Danmark) 
Liquid nitrogen tank (Cryoson, Schöllkrippen, Germany) 
Cell culture incubator (WTB, Tuttlingen, Germany) 
Microscope (Zeiss, Oberkochen, Germany) 
Pipettes, Tissue culture flasks, Centrifuge vials (Sarstedt, Nümbrecht, Germany) 
Sterile benches (BDK, Sonnenbühl, Germany) 
Sterile filters (Gelman Sciences, Ann Arbor USA) 
Neubauer® counting chamber (Brand, Wertheim, Germany) 
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3.6 Buffer, media, solutions 
ELECTROPHORESIS BUFFER (SDS-PAGE) 
25mM Tris, pH 8.3 
250mM Glycine 
0.1% (w/v) SDS 
SDS/ACRYLAMIDE GEL FOR WESTERN BLOT 
 Running gel (10%)   Stacking gel (10%) 
 40% (v/v) Acrylamide  40% (v/v) Acrylamide   
 1.5M Tris, pH 8.8   0.5M Tris, pH 6.8 
 10% (w/v) SDS   10% (w/v) SDS 
 10% (w/v) APS   10% (w/v) APS 
 0.0005% (v/v) TEMED  0.0005% (v/v) TEMED  
TAE (TRIS/ACETATE/EDTA) ELECTROPHORESIS BUFFER 
40mM Tris acetate 
 2mM Na2EDTA·2H2O 
TBE (TRIS/BORATE/EDTA) ELECTROPHORESIS BUFFER 
 890mM Tris  
 890mM Boric acid 
 10mM EDTA, pH 8.0 
SDS-PAGE GEL LOADING DYE (2X) 
125mM Tris·Cl, pH 6.8 
4% (w/v) SDS 
10% (v/v) b-Mercapto-ethanol 
30% (v/v) Glycerol 
0.004% (w/v) Bromophenol blue 
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WESTERN BLOT STRIPPING SOLUTION 
0.1M b-Mercapto-ethanol 
2% (w/v) SDS 
1M Tris, pH 6.8 
TE BUFFER 
10mM Tris·Cl, pH 8.0 
1mM EDTA 
ELECTROPHORESIS TANK BUFFER (WESTERN BLOT) 
125mM Tris  
960mM Glycine 
0.5% (w/v) SDS 
TRANSFER BUFFER, pH 8.5 
25mM Tris 
0.2M Glycine 
20% (v/v) Methanol 
TRIS-BUFFERED SALINE (TBS) 
100mM Tris·Cl, pH 7.5 
150mM NaCl 
TBST (TBS PLUS TWEEN20) 
100mM Tris·Cl, pH 7.5 
150mM NaCl  
0.05% (v/v) Tween20 
BLOCKING BUFFER 
TBS 
0.1% (v/v) Tween20 
5% (w/v) nonfat dry milk 
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PRIMARY ANTIBODY DILUTION BUFFER 
TBS 
0.05% (v/v) Tween20 
2.5% (w/v) nonfat dry milk 
PRIMARY ANTIBODY DILUTION BUFFER 
(FOR PHOSPHORYLATED PROTEINS) 
TBS 
0.05% (v/v) Tween20 
5% (w/v) BSA 
WHOLE CELL LYSIS BUFFER (RIPA LYSIS BUFFER) 
1% (v/v) NP40 
0.5% (w/v) Sodium deoxycholate 
0.1% (w/v) SDS 
0.15M NaCl 
5mM EDTA 
50mM Tris, pH 8.0 
10mM Sodium pyrophosphate 
50mM Sodium fluoride 
0.2mM Sodium orthovanadate 
1mM PMSF 
10mg/ml Pepstatin A, Leupeptin, Aprotinin, Antipain, Chymostatin 
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NUCLEAR EXTRACT BUFFERS 
Buffer A:    Buffer C: 
20mM HEPES, pH 7.9  10mM HEPES, pH 7.9 
25% (v/v) Glycerol   1.5mM MgCl2 
420mM NaCl    10mM KCl 
1.5mM MgCl2    0.5mM DTT 
0.2mM EDTA    0.2mM PMSF 
0.5mM DTT 
0.2mM PMSF 
EMSA BINDING BUFFER 
4mM HEPES, pH 7.9 
40mM KCl 
10mM MgCl2 
1mM Diothiothreitol (DTT) 
0.2mM Phenylmethylsulfonyl fluoride (PMSF) 
4% (v/v) Glycerol 
10X ANNEALING BUFFER FOR EMSA 
20mM Tris, pH 7.5 
10mM MgCl2 
50mM NaCl 
1mM DTT 
TRIS-GLYCINE ELECTROPHORESIS BUFFER FOR EMSA, pH 8.3 
0.25M Tris  
1.9M Glycine 
10mM EDTA 
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5.2% POLYACRYLAMIDE GEL FOR EMSA 
40% (v/v) Bisacrylamide 1:19 
890mM Tris  
890mM Boric acid 
10mM EDTA, pH 8.0 
10% (w/v) APS  
0.0005% TEMED 
5X BINDING BUFFER FOR EMSA 
4mM HEPES, pH 7.9 
40mM KCl 
10mM MgCl2 
1mM DTT 
0.2mM PMSF 
4% (v/v) Glycerol 
GROWTH MEDIUM FOR BACTERIA 
LB (luria bertani) medium with respective antibiotics 
MAMMALIAN CELL CULTURE MEDIA 
293T cell line 
DMEM 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1% (v/v) Penicillin-Streptomycin 
U937, U937/Zn2+-inducible AML1-ETO and Kasumi-1 cell lines 
RPMI 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1% (v/v) Penicillin-Streptomycin 
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U937/TET cell line  
RPMI 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1µg/ml Tetracycline 
0.5µg/ml Puromycin 
U937/TET/AML1-ETO cell line  
RPMI 
10% (v/v) FBS 
1% (v/v) L-Glutamine 
1µg/ml Tetracycline 
0.5µg/ml Puromycin 
1mg/ml G418  
Other buffers were provided by kits. 
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4. METHODS 
4.1 Cell culture methods 
INDUCIBLE CELL LINES 
U937/Zn2+-inducible AML1-ETO (U937Z/A-E) 
AML1-ETO cDNA is under the control of the human metallothionein promoter in the 
expression vector pPC18. Adding 100µM Zn2+ to the cell culture medium induced the 
expression of AML1-ETO. 
U937/TET-regulated AML1-ETO (U937T/A-E) 
AML1-ETO cDNA is under the control of the tetracycline-responsive transcriptional 
repressor tTA. For the induction of tetracycline-controlled AML1-ETO, cells were washed 
three times in 50ml of PBS and seeded at 1x105 cells/ml in the maintenance medium in the 
absence of tetracycline. 
PRIMING WITH G-CSF 
U937T/A-E cells were grown for 48 hours with or without tetracycline and subsequently 
treated with 10µM or 100µM of human recombinant G-CSF for 15 or 30 minutes. RIPA 
lysates were prepared and analyzed by Western blot for the amount of phosphorylated 
Thr183/Tyr185 in JNK. 
JNK INHIBITOR PEPTIDE 
U937T/A-E and U937T cells were grown for 72 hours in the presence or absence of 
tetracycline. 1µM of JNK specific inhibitor peptide or HIV-TAT 48-57 negative peptide 
control was added to the cells at the time of induction. 
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SUPERNATANT EXPERIMENTS 
Supernatants of 1x107 U937T/A-E and U937T cells were harvested 48 hours after removal 
of tetracycline. 1x107 wildtype U937 cells were centrifuged, the supernatant removed and 
the cell pellet resuspended with the supernatants of U937T/A-E or U937T cells. Wildtype 
U937 cells were incubated for 15 or 30 minutes with the supernatants and immediately kept 
on ice. Whole cells were lysed using RIPA buffer (see buffers) and the lysates were kept at 
-80°C. Lysates were analyzed by Western blot for expression of phosphorylated Ser63 in  
c-Jun and phosphorylated Thr183/Tyr185 in JNK. 
4.2 Transient transfections using Effectene® reagent 
Transient transfection using the Effectene® transfection kit allows transfection in the 
presence of FBS, which was prefered in this study because of the serum induced 
fluctuations in c-Jun expression.  
FOR ADHERENT CELLS 
293T cells were plated 24 hours prior to transfection at about 5x105 cells/ml in 75cm2 
flasks to achieve a 50-60% confluence on the day of transfection. In a 1.5ml Eppendorf 
tube, 2µg of DNA was diluted in 300µl of EC buffer (DNA condensation buffer, 
Effectene® transfection kit) and 16µl of Enhancer (Effectene® transfection kit). The 
Enhancer forms complexes with the transfected DNA. Complexes were vortexed for 1 
second and incubated for 2 to 5 minutes at room temperature. 20µl of Effectene® 
transfection reagent (Effectene® transfection kit) was added to the DNA enhancer 
mixture. The complex was vortexed for 10 seconds and incubated at room temperature 
for 5 to 10 minutes to allow transfection complex formation. During this period, the 
growth medium was gently aspirated from the cells and 12ml of fresh DMEM with FBS 
and antibiotics was added. The transfection complexes were pipetted drop-wise onto the 
cells with 1ml of DMEM containing FBS.  
The dish was gently swirled to ensure uniform distribution of the transfection complexes 
and cells were incubated for 48 hours at 37°C at 5% CO2. 
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FOR SUSPENSION CELLS 
24 hours prior to transfection, U937 cells were split to 3x105 cells/ml. On the day of 
transfection, 1x106 cells were plated in 1.6ml of medium with FBS and antibiotics into  
6 well plates. 1µg of DNA was diluted in 100µl of EC buffer (Effectene® transfection 
kit). 6µl Enhancer and 20µl of Effectene® transfection reagent (Effectene® transfection 
kit) were added, the solution was applied to the cell suspension with 600µl of RPMI 
medium with FBS and antibiotics and incubated for 30 hours.  
U937T or U937T/A-E cells were kept in the maintenance medium with or without 
tetracycline for 12 hours prior to transfection and harvested 24 hours after transfection.  
4.3 PCR cloning 
For generation of a human c-jun promoter construct ranging from bp -63 to bp +170 in 
pGL2, the fragment was amplified by PCR using pcjun -63/+170 Sense and Antisense 
primers (see primers). The c-jun promoter construct ranging from bp -79 to bp +170 served 
as a template. 1µl of the PCR product was immediately cloned into the plasmid vector 
pCR2.1 according to TOPO TA cloning strategy. Subsequently, the fragment was released 
by Kpn/XhoI digest and subcloned into the Kpn/XhoI site of pGL2 luciferase vector.  
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4.4 Reverse transcriptase PCR 
ISOLATION OF TOTAL RNA ACCORDING TO THE RNEASY® METHOD 
3x106 suspension cells (cell lines or peripheral blood monocytes of patient samples) 
were washed twice with PBS and transferred with 1ml of PBS into 1.5ml Eppendorf 
tubes. To disrupt and lyse the cells, cells were spun at 300g for 5 minutes and 
resuspended in 350µl of RLT buffer (RNeasy® RNA isolation kit). For homogenization, 
the lysate was transferred to a QIAshredder® column (RNeasy® RNA isolation kit) and 
centrifuged for 2 minutes at maximum speed in an Eppendorf tabletop centrifuge. 350µl 
of 70% ethanol were added to adjust the binding conditions and the sample was added to 
an RNeasy® mini spin column (RNeasy® RNA isolation kit), in which the RNA could 
absorb to the membrane. Contaminants were removed by wash spins at 10,000 rpm for 
15 seconds with 700µl of buffer RW1 (RNeasy® RNA isolation kit) and with 500µl of 
RPE buffer (RNeasy® RNA isolation kit). To wash out all of the ethanol, 500µl RPE 
buffer was added and another 2 minute-spin at maximum speed was performed. For 
RNA elution, the column was placed in a 1.5ml collection tube and 40µl of RNase-free 
water was directly pipetted onto the column and centrifuged for 1 minute at 10,000 rpm. 
Total RNA was stored at -80°C. 
FIRST-STRAND cDNA SYNTHESIS 
Reverse transcriptases (RT) with RNA dependent DNA polymerase activity synthesize 
complementary DNA (cDNA) from an RNA template for subsequent PCR or cloning 
experiments. 1µg of RNA was transcribed in 20µl of reverse transcriptase reaction 
containing 2µl of 5mM dNTPs, 2µl of 10x RT buffer (Omniscript® RT kit), 2µl of 
10µM 17mer oligo dT primer, 1µl of 10U/µl RNasin® RNase inhibitor, 1µl of 4U/µl 
Omniscript® reverse transcriptase (Omniscript® RT kit) and RNase-free water up to 
20µl. The cDNA synthesis mix was incubated for 90 minutes at 37°C and the cDNA was 
stored at -20°C. 
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SEMI-QUANTITATIVE RT-PCR 
We performed semi-quantitative hot-start PCR using a thermal cycler in order to 
optimize PCR conditions prior to performing quantitative real-time PCR. PCR was 
performed in 20µl containing 2µl cDNA template, 200µM of each dNTP, 1.5mM 
MgCl2, 0.7µM of sense and antisense primer and 2.5U Taq polymerase. PCR products 
were electrophoresed through a 1% agarose gel and visualized by ethidium bromide 
staining. 
QUANTITATIVE REAL-TIME PCR 
Quantitative real-time PCR using the LightCyclerT M (LC) real-time PCR system enables 
real-time monitoring of PCR product formation. PCR cycles, in which the PCR product 
increases logarithmically, can be identified and the initial concentration of the target 
DNA determined. We used the Fast Start DNA SYBR Green I kit. SYBR Green I dye is 
a fluorescence dye, which binds to double-stranded DNA. A fluorescence signal is being 
recorded at the end of each elongation phase and the increasing amounts of PCR product 
can be monitored from cycle to cycle.  
We quantified the expression of the transcription factors c-jun and AML1-ETO in U937 
cell lines with Zn2+-inducible expression of AML1-ETO and in t(8;21) positive patient 
samples relative to the expression of the housekeeping gene G6PD. We performed 
relative quantification of the target genes by forming ratios between the target genes and 
the housekeeping gene G6PD (target gene/G6PD). The initial concentrations of the 
target genes and the housekeeping gene G6PD were calculated using a standard curve. 
For this purpose, we serially diluted a G6PD plasmid: pGdBBX to 10,000fg, 1,000fg or 
100fg. Upregulation of c-jun upon AML1-ETO induction or the upregulation of   
AML1-ETO upon addition of Zn2+ were shown as fold upregulation compared to time 
point zero, which was set to 1. For the patient samples, values of target gene/G6PD 
ratios were directly compared to each other. 
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PCR was performed using 2ml of 10x mastermix solution (provided, contains Fast-Start 
Taq DNA polymerase, reaction buffer, dNTP mix, SYBR Green I dye and 10mM 
MgCl2), 2ml cDNA (from cell lines or patient samples), 4mM MgCl2, 7.5mM of each 
primer and RNase-free water to a final volume of 20ml. After 10 minutes initial 
denaturation at 95°C to activate the polymerase, amplification occurred in a three-step 
cycle procedure with denaturation at 95°C for 0 seconds, annealing at 64°C for             
10 seconds and extension at 72°C for 25 seconds. This three-step cycle was repeated 35 
times. Fluorescence of SYBR Green I was measured after each extension step at 530nm. 
The final PCR cycle was followed by a melting curve analysis to confirm PCR product 
identity and differentiate it from non-specific products (for example primer-dimer 
products). For the melting curve analysis, the products were denatured at 95°C, annealed 
at 65°C and then slowly heated up to 95°C with fluorescence measurement at 0.2°C 
increments. Amplification products from the LightCycler were checked by 
electrophoresis on 1% ethidium bromide stained agarose gels. The estimated size of the 
amplified fragments matched the calculated size: for c-jun: 409bp, G6PD: 343bp, G-CSF 
receptor: 276bp, G-CSF: 591bp and AML1-ETO: 250bp. 
4.5 Reporter assay for Firefly and Renilla luciferase 
We studied the effects of leukemic fusion genes or transcription factors on gene 
expression by transiently transfecting cells with plasmids containing the relevant 
promoters 5’ of a Firefly luciferase reporter gene. All samples were transfected with a 
Renilla luciferase “control” reporter plasmid. Normalizing the activity of the 
experimental reporter to the activity of the internal control reporter minimized 
experimental variability caused by differences in cell viability or transfection efficiency. 
The activities of Firefly luciferase of the experimental reporter and Renilla luciferase of 
the pRL-null control plasmid were measured sequentially from a single sample using the 
Dual-luciferase reporter assay system. 
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Transfected cells were washed twice with PBS and lysed in 100µl of Passive lysis buffer 
(Dual-luciferase reporter assay system) by agitation for 30 minutes. Passive Lysis buffer 
was provided as a 5x concentrate, diluted in ddH2O and stored at 4°C up to one month.  
The Luciferase assay reagent II (LARII) (Dual-luciferase reporter assay system) was 
resuspended in 10ml of Luciferase assay buffer and was storable for 1 month at -20°C or 
for 1 year at -70°C. The 50X Stop&Glo stock solution (Dual-luciferase reporter assay 
system), used to quench Firefly luciferase luminescence, was prepared by transferring 
200µl of Stop&Glo substrate solvent (Dual-luciferase reporter assay system) to the 
lyophilized Stop&Glo substrate (Dual-luciferase reporter assay system). This solution 
has to be kept on ice and was storable at -70°C for 1 month. Immediately before use, 1x 
Stop&Glo working solution was prepared with Stop&Glo buffer (Dual-luciferase 
reporter assay system) and kept on ice. 
20µl of cell lysate was diluted in 100µl of LARII and the Firefly luciferase 
luminescence of the transfected reporter plasmid measured using the TD20/20 
luminometer. After addition of 100µl Stop&Glo working solution, which quenched the 
Firefly luciferase, the remaining Renilla luciferase of the internal control plasmid     
pRL-null was measured. A ratio between Firefly and Renilla luciferase was calculated 
automatically.  
4.6 Cell lysates, in vitro translation 
RIPA LYSATES 
Adherent cells were scraped in 10ml of PBS. Subsequently, approximately 1x107 cells 
were washed twice in PBS by centrifuging the cells at 1,000 rpm for 10 minutes. 
Suspension cells were washed directly. Washed cells were resuspended in 1ml of PBS, 
transferred to 1.5ml Eppendorf tubes and spun for 10 seconds at maximum speed. The 
pellet was resuspended in 50µl of RIPA lysis buffer with proteinase and phosphatase 
inhibitors (see buffers) and incubated on ice for 30 minutes.  
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During incubation time, cell lysates were vortexed every 10 minutes. After incubation, 
lysates were spun at 4°C for 30 minutes at maximum speed. The supernatant was 
collected and stored immediately at -80°C. 
NUCLEAR EXTRACTS 
Adherent cells were scraped in 10ml of ice-cold PBS and approximately 1x107 cells 
were washed twice in PBS at 1,000 rpm for 10 minutes. Suspension cells were washed 
directly. Cell pellets were resuspended in 1ml of PBS, transferred to 1.5ml Eppendorf 
tubes and spun at 6,600 rpm for 20 seconds. Pellets were resuspended in 400µl cold 
Buffer A (see buffers), were swollen on ice for 15 minutes and vortexed for 10 seconds. 
The nuclei were pelleted in a tabletop centrifuge for 10 seconds at maximum speed. 
Subsequently, the nuclei pellets were resuspended in 40µl of Buffer C (see buffers) by 
pipetting up and down. This was followed by a 20-minute incubation period on ice, 
during which the tubes were flicked occasionally. The cell debris was pelleted at 
maximum speed for 3 minutes at 4°C and the supernatants were saved and stored at        
-80°C. 
IN VITRO TRANSLATION 
AML1-ETO and c-jun were in vitro transcribed and translated using the TnT® 
reticulocyte lysate system with SP6 polymerase and were labeled at amino acid 
methionine with Tran 35S-labelT M (>1000Ci/mmol at 10mCi/ml). For a 50µl reaction we 
used: 
TnT® rabbit reticulocyte lysate (provided)  25µl 
TnT® reaction buffer (provided)    2µl 
SP6 polymerase     1µl 
amino acid mixture minus methionine (provided) 1µl 
Tran 35S-labelTM (>1000Ci/mmol at 10mCi/ml)  4µl 
RNasin® RNase inhibitor (40U/µl)   1µl 
DNA template (1µg)     variable  
RNase-free water     up to 50µl 
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Reagents were mixed and incubated at 30°C for 90 minutes. 
4.7 Western blot analysis 
PROTEIN MEASUREMENT 
For measuring total protein concentration, we performed a colorimetric assay based on 
the Bradford-dye binding procedure103 according to the protocol of the Bio-rad protein 
estimation kit. The assay is based on the color change of Coomassie blue in response to 
various concentrations of protein. We mixed 20µl of 1:20 diluted protein lysate with 1ml 
of 1:5 diluted reagent dye, incubated the mixture for 15 minutes and determined the 
color change at 595nm using a spectrophotometer. We included BSA protein standards 
of known concentrations for generating a standard curve with which we could calculate 
the protein concentration in µg/µl.  
SDS-PAGE AND WESTERN BLOT 
Lysates containing 100µg of proteins were diluted in 2x SDS-PAGE gel loading dye 
(see buffers) and boiled at 95°C for 5 minutes. Proteins were electrophoretically 
separated according to their molecular weight through a 10% SDS/Acrylamide gel (see 
buffers) at 125 volts. 10µl of molecular weight standard was included in each gel. The 
separated proteins were wet-transferred to ImmobilonTM-P transfer membranes, which 
had been pre-soaked in methanol, rinsed with ddH20 and kept in transfer buffer (see 
buffers) for 15 minutes. The transfer cassette was prepared in the following sequence: 
sponge > blotting paper > gel > transfer membrane > blotting paper > sponge. The 
transfer chamber was filled with transfer buffer and the proteins were transferred at 100 
volts for 90 minutes at 4°C. After the transfer, the membrane was blocked for 2 hours in 
a blocking buffer (see buffers) to prevent unspecific binding of the antibodies to the 
membrane. The blocked membrane was washed three times with TBST (see buffers) to 
get rid of excess blocking solution and the primary antibody was added at a dilution of 
1:1,000 and incubated overnight at 4°C.  
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Antibodies recognizing phosphorylated proteins were diluted in TBST with 1% (w/v) 
BSA, antibodies against unphosphorylated proteins in TBST with 2.5% (w/v) nonfat dry 
milk. After three 5-minute washes with TBST, the appropriate peroxidase-linked 
secondary antibody diluted 1:2,000 in TBST with 2.5% (w/v) nonfat dry milk was added 
and incubated for 1 hour at room temperature.  
After a final washing step, four 5-minute washes with TBST, the proteins were detected 
using chemiluminescence. For that, the two ECL® solutions of the ECL® detection 
system were mixed in equal quantities (2 + 2ml for an 8 x 10cm membrane) and added 
to the moist membrane for 1 minute. The blot was immediately exposed to a film for 
approximately 60 seconds and developed. This method allows „stripping“ the membrane 
up to three times and performing different immunodetections on the same blot. In this 
study, each blot was stripped and re-blotted with an anti b-tubulin antibody in order to 
control for even protein loading. For stripping, the membrane was rotated in the 
waterbath at 55°C for 30 minutes in stripping solution (see buffers), rinsed 1x with 
TBST, blocked for 2 hours and incubated with the primary antibody as described above. 
SAPK/JNK ASSAY KIT 
We employed a non-radioactive method using the SAPK/JNK assay kit to measure c-Jun 
phosphorylating activity at residues Ser63 and Ser73 in c-Jun, which is generally JNK 
specific. 250µg protein of whole cell lysates was incubated overnight with N-terminal  
c-Jun (amino acids 1-89) fusion protein bound to glutathione sepharose (GST) beads to 
pull down JNK. Amino acids 1-89 in c-Jun contain a high-affinity binding site for JNK 
just N-terminal to the Ser63 and Ser73 phosphorylation sites. The beads were washed 
twice with a provided cell lysis buffer (SAPK/JNK assay kit), followed by two washes 
with a provided kinase buffer (SAPK/JNK assay kit). The kinase reaction was carried 
out during a 30-minute incubation period at 30°C in the presence of non-radioactive 
ATP. The reaction was terminated with 25µl of 2x SDS-PAGE gel loading dye (see 
buffers) and c-Jun phosphorylation was measured by Western blot using an antibody 
against phosphorylated Ser63 in c-Jun, which is usually JNK specific.  
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Using this method, the possibility cannot be ruled out that kinases other than JNK 
phosphorylate Ser63 in c-Jun. The serine/threonine kinase c-Raf-1/c-mil, for example, 
has been shown to phosphorylate Ser63 in c-Jun in a JNK independent manner. For 
verification, we confirmed the results obtained by the SAPK/JNK assay kit by directly 
measuring phosphorylated Thr183/Tyr185 in JNK by Western blot. 
To rule out direct binding of JNK to GST, lysates were incubated with GST beads alone. 
Blots were stripped and reblotted with a GST antibody to control for variability in gel 
loading.  
4.8 Electrophoretic mobility shift assay (EMSA) 
PREPARATION OF DOUBLE-STRANDED OLIGONUCLEOTIDES 
20µg of two complementary oligonucleotides were diluted in a total volume of 100µl of 
1x annealing buffer (see buffers). The oligonucleotide mix was heated to 95°C for          
5 minutes and slowly cooled down in order to anneal the complementary 
oligonucleotides (for example by switching off the water bath and allowing to cool 
overnight). Double-stranded oligonucleotides were stored at -20°C. 
LABELING OF THE PROBE 
10µl of double-stranded oligonucleotides were diluted in 70µl of 1x annealing buffer to 
make a 50ng/µl oligonucleotide stock. In 20µl labeling reaction, 1µl of the 50ng/µl 
oligonucleotide stock was mixed with 2µl of 10x polynucleotide kinase buffer, 5µl of 
10mCi/ml [g-32P]ATP (3000Ci/mmol), 2µl of polynucleotide kinase (10,000U/ml) and 
ddH2O. The reaction was incubated for 1 hour at 37°C. To remove un-incorporated 
oligonucleotides, the labeled oligonucleotides were purified using QuickSpin® columns. 
For that, the columns were pre-centrifuged at 1,000 rpm for 2 minutes to remove the 
buffer and then 20µl of labeled oligonucleotides were added to the column and spun for 
5 minutes at 2,800 rpm. The labeled oligonucleotides were stored in a lead box at -20°C. 
 
4. Methods  36 
_________________________________________________________________________ 
 
GELSHIFT ASSAY 
A 5.2% polyacrylamide gel (see buffers) was prepared and polymerised for 20 to 30 
minutes. The wells were rinsed with a 1ml pipette and the gel was pre-run for               
30 minutes at 140 volts. Meanwhile, the 20µl binding reaction was prepared in the 
following sequence: 4µl of 5x binding buffer (see buffers) > 2µl of poly(dI-dC) as a   
non-specific competitor DNA > ddH2O > Protein > 200 fold molar excess (100ng) of 
unlabeled competitor oligonucleotides > 1µl of labeled probe. As a protein source, we 
used either 5µg of nuclear extracts or 3µl of in vitro translated protein or unprogrammed 
reticulocyte lysate. The reaction was incubated for 30 minutes at room temperature. For 
supershift experiments, 3ml of 200mg IgG/0.1ml antibody was added and incubated for 
another 30 minutes at room temperature. Reactions were electrophoresed at 130 volts at 
4°C, dried and placed on x-ray film at -80°C with an intensifying screen.  
4.9 AnnexinV apoptosis assay 
In the early apoptotic process, phospholipid asymmetry is disrupted leading to the 
exposure of phosphatidylserine on the outer leaflet of the cytoplasmic membrane. 
AnnexinV is an anticoagulant protein that preferentially binds negatively charged 
phospholipids. We used AnnexinV-FITC conjugates for rapid detection of apoptotic 
cells by flow cytometry. Cells were washed twice with PBS containing 2% of FBS at 
1,600 rpm for 5 minutes and softly vortexed in between. Then, 2µl of 50mg/ml 
AnnexinV-FITC and 2ml of 50mg/ml propidium iodide were added in a total volume of 
100µl of AnnexinV binding buffer and incubated for 20 minutes in the dark. 
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ANALYSIS BY FLOW CYTOMETRY 
10,000 cells were analyzed by flow cytometry. The X-axis of the dot blot reflected the 
logarithmic AnnexinV-FITC fluorescence and the Y-axis the propidium iodide 
fluorescence. Thus, unlabeled viable cells appeared in the lower left quadrant, early 
apoptotic cells that have bound AnnexinV in the lower right quadrant and late apoptotic 
or necrotic cells that have taken up the propidium iodide appeared in the upper right 
quadrant of the dot blot. We compared the percentage of AnnexinV-FITC positive cells.  
4.10 Statistical analysis 
To compare the median of two groups, we performed the Mann-Whitney Wilcoxon test. 
In this study, we compared the absolute signal intensities for c-jun expression analyzed 
by microarray analysis (Affymetrix chips). The signal intensity for c-jun expression in 
each of the most frequent AML-associated translocations was compared to c-jun 
expression in normal bone marrow cells and the differences analyzed for their statistical 
significance. A p-value =0.05 indicated statistically significant differences between two 
groups. 
In order to analyze whether there is a positive correlation between two factors within the 
same group, in our case between the mRNA expression of c-jun and the mRNA 
expression of AML1-ETO in t(8;21) positive patient samples, we calculated a Pearson 
correlation coefficient (r). r represents the deviation of two factors from a regression line. 
r=1 reflects the optimum, in the case of two factors lying directly on the regression line. 
The respective p-value for r was calculated for statistical significance. A p-value =0.05 
indicated statistical significance. 
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5. RESULTS 
5.1. High c-jun mRNA expression levels in leukemia patient 
cells with t(8;21), t(15;17) or inv(16), and correlative mRNA 
expression levels for AML1-ETO and c-jun within t(8;21) 
positive leukemia patient cells 
CML leukemia cells with the translocation t(9;22) have previously been associated 
with increased c-jun expression. Thus, we examined whether mRNA expression levels for 
c-jun are also elevated in AML leukemia cells with the most common cytogenetic 
abnormalities. Microarray analysis was performed of AML patient cells with translocation 
t(8;21), t(15;17), inv(16), translocations involving the mixed lineage leukemia (MLL) gene 
on chromosome 11q23: t(11q23/MLL), or of normal bone marrow cells, in a co-operation 
with the Leukemia Diagnostic Department, Klinikum Großhadern, Munich.  
In the present study this data was statistically analyzed for the expression of human 
c-jun. We found that in normal bone marrow cells, c-jun mRNA expression levels were 
consistent with a standard deviation of 18.7 (Figure 1). Therefore, c-jun mRNA expression 
levels in normal bone marrow cells served as a reference point to which we compared the 
mean and standard deviations of c-jun mRNA expression levels in leukemia patient cells. 
We found increased expression of c-jun mRNA in t(8;21), t(15;17) or inv(16) positive 
primary leukemia patient cells. This increase was statistically significant when compared to 
expression levels of c-jun mRNA in normal bone marrow cells (Figure 1). There was, 
however, no statistically significant change between c-jun mRNA expression levels in 
t(11q23/MLL) positive leukemia patient cells and normal bone marrow cells, indicating 
that t(11q23/MLL) positive patient cells had basal levels of c-jun mRNA expression. CML 
patient cells with t(9;22) were included as positive controls. These had significantly higher 
c-jun mRNA expression levels (Figure 1). 
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Standard deviations of c-jun mRNA expression levels in t(8;21), t(15;17) or inv(16) 
positive leukemia patient cells were about 4 times higher compared to normal bone marrow 
cells (Figure 1). In the case of t(8;21), for which the standard deviation was highest, we 
therefore investigated whether the high variation in c-jun mRNA expression levels was a 
consequence of fluctuating mRNA expression levels of AML1-ETO.  
We performed real-time PCR for AML1-ETO (Figure 2A) and c-jun (Figure 2B) of 
16 t(8;21) positive patient samples and found a 13 fold variation between the mRNA 
expression levels of AML1-ETO and c-jun. In order to determine whether these variations 
were correlated, the average ratios of c-jun (Figure 2B) and AML1-ETO (Figure 2C) 
mRNA expression levels were compared by correlation analysis. We found statistically 
significant correlation between c-jun and AML1-ETO mRNA expression levels within 
t(8;21) patient samples with a p-value =0.01 (Figure 2C).  
This data indicates that t(8;21), t(15;17) or inv(16) positive leukemic AML patient 
cells contain significantly higher mRNA expression levels of c-jun than normal bone 
marrow cells. Furthermore, within t(8;21) positive AML patient cells, the mRNA 
expression levels of AML1-ETO and c-jun are correlated. 
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Figure 1: High c-jun mRNA expression in leukemia patient cells with t(8;21), 
t(15;17), inv(16) or t(9;22) compared to normal bone marrow cells.  
Comparison of absolute signal intensities for c-jun mRNA expression from microarray 
analysis (Affymetrix) of leukemia patient cells with t(8;21), t(15;17), inv(16), t(9;22), or 
t(11q23/MLL) to normal bone marrow (BM) cells. Number of patients analyzed (n) and the 
standard deviation (S.D.) is given for each group. The median c-jun expression of these 
leukemic translocations was statistically compared to c-jun expression in normal bone 
marrow cells using the Mann-Whitney Wilcoxon test. A p-value £0.05 indicates statistical 
significance. 
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Figure 2: Highly significant correlation between c-jun and AML1-ETO mRNA 
expression levels within t(8;21) positive AML cells. 
(A) Real-time PCR for AML1-ETO (A-E) and G6PD of 16 t(8;21) positive AML patient 
samples. Ratios for A-E/G6PD were compared to each other. Data is shown as mean             
± standard deviation (S.D.) of 2 different experiments. Patient numbers 3, 5, 6, 8, 10, 12 
and 15 have only been analyzed once for the expression of A-E/G6PD. 
(B) Real-time PCR for c-jun of the same patient samples as described in (A). Ratios of      
c-jun/G6PD are given. Data is shown as mean ± S.D. of 2 different experiments.  
(C) Correlation analysis: Average ratios for c-jun/G6PD and A-E/G6PD expression of      
16 t(8;21) positive AML patient samples are plotted as an xy scatter plot. Correlation 
coefficient (r) and p-value are shown. A p-value £0.05 indicates statistical significance. 
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5.2 AML1-ETO induction increases c-jun mRNA and c-Jun 
protein expression  
To demonstrate that AML1-ETO itself is responsible for the increased c-jun mRNA 
expression levels in t(8;21) positive patients samples, we used a myeloblastic U937 cell 
line with AML1-ETO under the control of a zinc-inducible metallothionein promoter 
(U937Z/A-E) and performed quantitative real-time PCR for AML1-ETO and c-jun at 
different time points of AML1-ETO induction. In this inducible system, AML1-ETO was 
maximally expressed (6 fold) after 2 hours of Zn2+-induction and slowly decreased 
thereafter (Figure 3A, upper panel). As shown in Figure 3A, middle panel, AML1-ETO 
expression induced an approximately 5 fold increase in c-jun expression after 4 and 6 hours 
of Zn2+-induction and c-jun levels remained elevated at 16 hours of induction. The addition 
of Zn2+ did not affect c-jun expression in control parental U937 cells (Figure 3A, lower 
panel). 
To investigate whether c-Jun protein levels are also affected upon AML1-ETO 
induction, Western blot experiments were performed using a tetracycline-regulated   
AML1-ETO expressing U937 cell line (U937T/A-E). This cell line expresses high and 
tightly controlled levels of AML1-ETO protein upon tetracycline withdrawal that can be 
easily quantified by Western blot analysis (Figure 3B, upper panel).88 c-Jun protein 
expression increased between 24 and 48 hours of AML1-ETO induction in the U937T/A-E 
cell line (Figure 3B, middle panel), whereas c-Jun expression remained unchanged in the 
U937T control cell line (Figure 3B, lower panel). 
Thus, expression analysis by real-time PCR or Western blot using two different 
inducible systems for AML1-ETO, clearly showed upregulation of c-jun mRNA or c-Jun 
protein expression, respectively, upon AML1-ETO induction in myeloid U937 cells. 
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Figure 3A: Upregulation of c-jun mRNA expression upon AML1-ETO induction. 
Real-time PCR analysis for AML1-ETO (A-E) and c-jun. U937Z/A-E and U937 cells were 
washed twice in phosphate-buffered saline (PBS) and stimulated with 100mM Zn2+           
for 1, 2, 4, 6, 8, 12 or 16 hours (h Zn2+). cDNA was prepared and tested for expression of  
c-jun, AML1-ETO (A-E) and housekeeping gene G6PD using real-time PCR technology. 
Ratios of c-jun/G6PD (middle panel) and A-E/G6PD (upper panel) are shown as fold 
upregulation compared to time point zero (no addition of Zn2+), which was set to 1 fold. 
Wildtype U937 cells were analyzed for c-jun expression to control for Zn2+effects (lower 
panel). Data is shown as mean ± S.D. of 3 different experiments. 
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Figure 3B: Upregulation of c-Jun protein expression upon AML1-ETO induction.  
Western blot analysis using whole cell lysates of U937T/A-E and U937T cell lines. Cells 
were washed three times with PBS and grown for 24, 48, 72 or 90 hours in the maintenance 
medium with tetracycline (+tet: no AML1-ETO expression), or without tetracycline           
(-tet: AML1-ETO expression). Western blot analysis for AML1-ETO using an anti ETO 
antibody (a ETO) of U937T/A-E cell lysates is shown in the upper panel. Kasumi-1 cell 
lysates containing AML1-ETO were included as positive controls. The middle panel shows 
the same U937T/A-E cell lysates examined for expression of c-Jun. In the lower panel, the 
empty vector U937T cell lysates were blotted for c-Jun to control for tet-off effects on       
c-Jun protein expression. In vitro translated (ivt.) AML1-ETO (A-E) and c-Jun proteins 
were included as controls in order to verify protein sizes. Reticulocyte lysate (ret. lys.) 
represents a negative control for in vitro translation containing only reticulocyte lysate. 
Every blot was stripped and reblotted for ß-tubulin as a loading control. 
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5.3 AML1-ETO enhances the positive autoregulatory activity of 
c-Jun by transactivating the human c-jun promoter through 
the proximal AP-1 site 
Next, we studied whether the increased level of c-Jun protein upon AML1-ETO 
expression resulted from direct stimulation of the human c-jun promoter. Furthermore, it 
was of interest to compare the transactivating capacity of AML1-ETO to wildtype AML1 
and ETO protein. Thus, we transiently transfected U937 cells with the full-length human   
c-jun promoter controlling the luciferase reporter gene and co-transfected AML1-ETO, 
AML1 or ETO. AML1 alone has been shown to be a weak transactivator, therefore, we 
also co-transfected AML1 and its co-activator CBFb together, which have been shown to 
co-operatively upregulate the M-CSF receptor promoter104 (Figure 4B, lower panel, right). 
AML1-ETO transactivated the full-length human c-jun promoter around 3 fold, 
whereas neither wildtype AML1, with or without CBFb, nor wildtype ETO showed 
transactivation capacity (Figure 4B, upper panel). A minimal promoter for NF-?B fused to 
the luciferase gene, which was not transactivated upon AML1-ETO, served as a negative 
control (Figure 4B, lower panel, left). Since ETO has not been described to be capable of 
DNA binding, there was no positive control available. 
Thus, we concluded that AML1-ETO transactivation capacity on the c-jun promoter 
is an acquired function of the fusion protein. 
We next went on mapping the site in the c-jun promoter being transactivated by 
AML1-ETO by transiently transfecting various 5’ c-jun promoter deletion mutants11 into 
U937 cells. The site in the c-jun promoter being transactivated by AML1-ETO could be 
narrowed down to a region between bp -180 to bp +731 (around 3.5 fold upregulation of   
c-jun promoter activity) and bp -63 to bp +731 (upregulation of c-jun promoter activity was 
lost) (Figure 4C).  
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Interestingly, in the longer c-jun promoter constructs ranging from bp -1780 to                   
bp -345/+731, transactivation capacity of AML1-ETO decreased up to 1.5 fold, which 
implies loss of positive response elements (Figure 4C). The increase in c-jun activation by 
AML1-ETO upon removal of the sequence from bp -345 to bp -180 suggests the presence 
of a repressive element (possibly the upstream AP-1 site). The bp -180 to bp +731 c-jun 
promoter construct still contains the proximal AP-1 site (see Figure 4A).  
Importance of the AP-1 site for AML1-ETO transactivation has previously been 
shown for a minimal AP-1 promoter derived from the collagenase gene in fibroblast cells.49 
Therefore, for fine mapping, we transiently transfected U937 cells with a c-jun promoter 
construct ranging from bp -79 to bp +170 or the same construct with the proximal AP-1 site 
mutated. Co-transfection of AML1-ETO transactivated the bp -79 to bp +170 c-jun 
promoter construct up to 4.5 fold. Transactivation capacity was reduced to 1.5 fold when 
the proximal AP-1 site was mutated and lost when we transfected a bp -63 to bp +170 
construct which was included to rule out importance of the 3’ promoter region between    
bp +170 and bp +731 (Figure 4D). 
These results indicate that in U937 cells, AML1-ETO increased AP-1 activity of the 
c-jun promoter via the proximal AP-1 site.  
Strikingly, the proximal AP-1 site is also the site to which c-Jun can feed back to 
autoregulate its expression. Thus, we hypothesized that AML1-ETO might enhance the 
autoregulatory capacity of c-Jun by increasing the amount of c-Jun protein. Therefore, we 
transiently transfected the bp -79 to bp +170 c-jun promoter construct and co-transfected   
c-jun, AML1-ETO or c-jun and AML1-ETO together into U937 cells, which contain only 
little endogenous c-Jun. AML1-ETO alone transactivated the c-jun promoter construct 
around 4 fold, c-jun transactivated its own promoter around 30 fold and upon                   
co-transfection of AML1-ETO around 90 fold (Figure 4E).  
These results suggest that c-jun and AML1-ETO co-operatively transactivate the    
c-jun promoter and that AML1-ETO enhanced the autoregulatory nature of c-jun. 
5. Results  48 
_________________________________________________________________________ 
 
 
Figure 4A: Schematic representation of the proximal human c-jun promoter   
with important transcription factor binding sites in myeloid cells.  
The proximal c-jun promoter contains 2 AP-1 sites, a proximal (pAP-1) and a distal    
(dAP-1) one, a CAAT binding site for CCAAT/enhancer binding proteins (C/EBPs) and 
binding sites for the transcription factors NF-jun, SP-1 and GATA-1. 
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Figure 4B: AML1-ETO but not wildtype AML1 or ETO transactivates the       
full-length human c-jun promoter. 
Upper panel: Effect of AML1-ETO, AML1, CBFß or ETO on the transactivation capacity 
of the full-length human c-jun promoter (pcjun -1780/+731). U937 cells were transiently 
transfected with 0.6mg of the full-length human c-jun promoter or the promoterless vector 
pGL3. 0.05mg of the internal control plasmid pRL-null was added in all transfections. 
0.2mg of expression plasmids for AML1-ETO (A-E), AML1, CBFß or ETO in pCMV5, or 
empty vector alone were co-transfected and luciferase activities determined 30 hours after 
transfection. The normalized luciferase activity of each c-jun promoter construct was 
arbitrarily defined as 1 fold promoter activity. The promoter activity in presence of   
AML1-ETO was presented in relation to it (fold promoter activity). Thus, effects of  
AML1-ETO on the empty vector plasmid (pGL3) could be more visible. Transfection data 
is shown as mean ± standard deviation (S.D.) of 3 separate experiments.  
Lower panel, left: Negative control for the transactivation capacity of AML1-ETO (A-E). 
U937 cells were transiently transfected with 0.6mg of a minimal NF-?B promoter and the 
same construct with mutated NF-?B site. 0.2mg of A-E was co-transfected and the promoter 
activity determined. Promoter activity upon co-transfection of AML1-ETO was presented 
in relation to the promoter activity of the NF-?B promoter construct, which was arbitrarily 
set to 1 fold. Transfection data is shown as mean ± S.D. of 3 separate experiments. 
Lower panel, right: Positive control for the transactivation capacities of AML1 and CBFß. 
The macrophage-colony stimulating factor receptor promoter (pMCSF-R) was transiently 
transfected into U937 cells and 0.2µg of AML1 and CBFß was co-transfected. Data was 
presented as described above. 
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Figure 4C: Mapping of the AML1-ETO responsive site in the human c-jun 
promoter. 
0.6mg of 5’ truncation mutants of the human c-jun promoter (pcjun -1780, -952, -719, -345, 
-180, -63/ +731) were transiently transfected into U937 cells and co-transfected with 0.2mg 
of pCMV5 AML1-ETO expression plasmid. The normalized luciferase activity of each     
c-jun promoter construct was arbitrarily defined as 1 fold. The promoter activity in 
presence of AML1-ETO was presented in relation to it (fold promoter activity). 
Transfection data is shown as mean ± S.D. of 3 separate experiments. 
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Figure 4D: Fine mapping of the AML1-ETO responsive site in the proximal c-jun 
promoter.  
Transient transfection of U937 cells with 0.6mg of a proximal c-jun promoter construct 
(pcjun -79/+170) or the same construct with the proximal AP-1 site mutated                
(pcjun -79/+170 mAP-1), with a bp -63 to bp +170 c-jun promoter construct                
(pcjun -63/+170) or the empty vector pGL2. 0.1mg of the expression plasmid pCMV5 
AML1-ETO (A-E) was co-transfected and promoter activity analyzed. The normalized 
luciferase activity of each c-jun promoter construct was arbitrarily defined as 1 fold. The 
promoter activity in presence of AML1-ETO was presented in relation to it (fold promoter 
activity). Transfection data is shown as mean ± S.D. of 3 separate experiments. 
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Figure 4E: Co-operative transactivation of the c-jun promoter by                 
AML1-ETO and c-jun.  
U937 cells were transiently transfected with 0.6µg of a proximal c-jun promoter construct 
(pcjun -79/+170) or the empty vector pGL2 and co-transfected with 0.1µg of AML1-ETO   
(A-E), c-jun, or A-E and c-jun together. Transfection was performed and the data analyzed 
as described above. 
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5.4 AML1-ETO cannot directly bind to the c-jun promoter 
To investigate whether AML1-ETO enhanced AP-1 activity of the c-jun promoter 
by directly binding to DNA, we performed electrophoretic mobility shift assays (EMSA). 
As described in Figure 5A, nuclear extracts of AML1-ETO transfected 293T cells could not 
specifically bind to a c-jun promoter oligonucleotide ranging from bp -88 to bp -28: pcjun 
(-88/-28) oligo, but positively bound to a control AML1 consensus site oligonucleotide 
(AML1 binding site oligo) (Figure 5B). Along with these results, DNA binding of    
AML1-ETO has only been shown through the wildtype AML1 consensus site 
TG(T/c)GGT,62 which is absent in the human c-jun promoter.  
Thus, we concluded that AML1-ETO might transactivate the human c-jun promoter 
in an indirect manner. 
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Figure 5: No physical binding of AML1-ETO to the proximal c-jun promoter.  
(A) Electrophoretic mobility shift assay (EMSA) with a proximal c-jun promoter 
oligonucleotide: pcjun (-88/-28) oligo. Oligonucleotide probes were incubated with 5mg of 
nuclear extracts of AML1-ETO transfected 293T cells (293T/A-E), or were mock 
transfected with the empty vector pCMV5 (293T/EV). 200 fold molar excess of unlabeled 
competitor self-probe (+comp) was added to the electrophoretic mobility shift assay. No 
specific supershifting of the band-shift complexes (non-specific bands were marked with     
an asterisk *) were produced with anti ETO (a ETO) or anti AML1 (a AML1) antibodies. 
Anti IgG (a IgG) antibody was added as an isotype control. In vitro translated c-Jun        
(ivt c-Jun) was used as a positive binding control to the c-jun promoter oligonucleotide and 
produced a specific shift (s) which could be competed away with 200x of competitor, was 
supershifted (ss) with c-Jun antibody and was absent in reticulocyte lysate (ret. lys.).  
(B) EMSA as described above using an oligonucleotide containing an AML1 binding site 
(AML1 binding site oligo) as positive binding control for nuclear extracts of AML1-ETO 
transfected 293T cells (293T/A-E).  
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5.5 AML1-ETO induces the JNK signaling pathway 
The c-jun promoter integrates several MAPK signaling pathways.105 At the 
proximal AP-1 site, pre-bound c-Jun is mainly targeted by the JNK signaling pathway,106 
which increases transcriptional activity of c-Jun by phosphorylating Ser63 and Ser73 in     
c-Jun.17,18 Therefore, the JNK signaling pathway might be involved in the indirect 
stimulation of the c-jun promoter by AML1-ETO. 
We assayed the activity of JNK induced phosphorylation of Ser63 in c-Jun in 
U937T/A-E cells after 48 hours of AML1-ETO induction (U937T/A-E 48h -tet). U937T 
cells were included as a negative control (U937T 48h -tet). As shown in Figure 6A, 
phosphorylation of Ser63 in c-Jun was increased upon AML1-ETO induction in the  
AML1-ETO expressing cell lysates (lanes 3 and 4), whereas no effect on c-Jun 
phosphorylation was seen upon tetracycline withdrawal in the U937T control lysates 
(Figure 6A, lanes 1 and 2). 
In order to rule out the possibility that kinases other than JNK phosphorylate Ser63 
in c-Jun,107 we directly measured the phosphorylation of JNK upon AML1-ETO induction. 
AML1-ETO induction for 48 hours increased phosphorylation of the 46 and the 54 kDa 
isoforms of JNK1 and JNK2,108 and was maximally increased at 72 hours. There was no 
upregulation of JNK phosphorylation in the U937T control cell lysates (Figure 6B). To 
investigate whether AML1-ETO induction influenced the expression of JNK, we analyzed 
the same blot for JNK1 expression, which was not enhanced upon AML1-ETO induction 
(Figure 6B).  
We further analyzed the phosphorylation of the endogenous JNK targets c-Jun and 
ATF-2 upon AML1-ETO expression. AML1-ETO induction for 48 and 72 hours increased 
JNK specific phosphorylation of Ser63 and Ser73 in c-Jun and Thr71 in ATF-2 by Western 
blot analysis (Figure 6C). There was a non-specific tetracycline-off effect on 
phosphorylation of c-Jun and ATF-2 at 24 hours in the U937T control cell line, which was, 
however, only transient and not visible at 48 and 72 hours of tetracycline withdrawal. 
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These results suggest that AML1-ETO activated the JNK pathway by inducing the 
phosphorylation of JNK and its targets c-Jun and ATF-2. 
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Figure 6A: AML1-ETO induces JNK specific activation of c-Jun. 
In vitro kinase assay for JNK. Cell lysates of U937T and U937T/A-E cells, grown for       
48 hours in the presence (+tet) or absence (48h -tet) of tetracycline, were incubated with  
GST N-terminal c-Jun (amino acids 1-89) fusion beads (lanes 1-4) or GST beads alone 
(lanes 5 and 6). Kinase reaction was triggered and indirectly analyzed by performing 
Western blot for JNK dependent phosphorylation of Ser63 in c-Jun: c-JunP (Ser63). As a 
control for even protein loading, the same blot was stripped and reblotted with a GST 
antibody.  
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Figure 6B: AML1-ETO induces phosphorylation of JNK. 
Western blot using an antibody against phosphorylated Thr183 and Tyr185 in JNK, which 
recognizes JNK isoforms of 46 and 54 kDa (JNKP p46, JNKP p54). Cell lysates of U937T 
and U937T/A-E cells were grown with tetracycline, or for 24, 48, or 72 hours without 
tetracycline. Blots were stripped and reblotted with an anti JNK1 antibody (a JNK1) to 
determine JNK1 expression, stripped again and reblotted for ß-tubulin as loading control. 
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Figure 6C: AML1-ETO induces phosphorylation of the JNK targets c-Jun and 
ATF-2. 
Western blot for phosphorylated Ser63 in c-Jun: c-JunP (Ser63), phosphorylated Ser73 in  
c-jun: cjunP (Ser73) and for phosphorylated Thr71 in ATF-2: ATF-2P (Thr71) using cell 
lysates of U937T and U937T/A-E cells grown for 24, 48 or 72 hours in the presence or in 
the absence of tetracycline. Each blot was re-blotted for ß-tubulin to control for protein 
loading.  
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5.6 Increased DNA binding of c-Jun and ATF-2 to the proximal 
AP-1 site of the c-jun promoter upon AML1-ETO induction 
The proximal AP-1 site is preferentially occupied by the AP-1 transcription factors 
and JNK targets c-Jun and ATF-2, which were both phosphorylated upon AML1-ETO 
induction. Therefore, we investigated by EMSA whether c-Jun and ATF-2 also bind to the 
proximal AP-1 site of the c-jun promoter in U937 cells and whether AML1-ETO induction 
has any effect on AP-1 composition or DNA binding capacity.  
Nuclear extracts of U937T/A-E or U937T cells, grown for 48 hours under 
tetracycline removal, served as a protein source. EMSA revealed that in U937 cells, c-Jun 
and ATF-2 could bind to the proximal AP-1 site of the c-jun promoter, but not c-fos. 
Binding to the proximal AP-1 site was confirmed by performing EMSA using a c-jun 
promoter oligonucleotide with mutated AP-1 site. AML1-ETO induction for 48 hours in the 
U937T/A-E cells (U937T/A-E) did not change the composition of AP-1 factors binding to 
the proximal AP-1 site compared to nuclear extracts of U937T control cells (Figure 7A). 
However, EMSA with increasing concentrations of specific competitor DNA revealed that 
upon AML1-ETO expression, the DNA binding of c-Jun and ATF-2 to the c-jun promoter 
was increased (Figure 7B).  
These results indicate that in U937 cells c-Jun and ATF-2 can bind to the proximal 
AP-1 site of the c-jun promoter. Thus, via phosphorylating c-Jun and ATF-2, the JNK 
signaling pathway might connect AML1-ETO to the proximal AP-1 site of the c-jun 
promoter. Furthermore, via stimulating the JNK pathway, AML1-ETO enhanced the DNA 
binding capacity of c-Jun and ATF-2 to the proximal AP-1 site, which might result in 
enhanced c-jun promoter activity. 
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Figure 7A: c-Jun and ATF-2 bind to the proximal AP-1 site in U937 cells. 
EMSA using a bp -88 to bp -28 c-jun promoter oligonucleotide: pcjun (-88/-28) (left panel) 
or a bp -88 to bp -28 c-jun promoter oligonucleotide with mutated AP-1 site: pcjun            
(-88/-28) mAP-1 (right panel). Nuclear extracts of U937T cells (U937T) and U937T/A-E 
cells (U937T/A-E), both grown under tetracycline withdrawal for 48 hours, were compared. 
Equal quantities of nuclear extracts were added to the binding reaction and produced a 
doubled-banded shift, of which the slower migrating band was supershifted with c-Jun or 
ATF-2 antibodies, but not with antibodies against c-fos. The faster-migrating band was 
supershifted neither with c-Jun nor with ATF-2 or c-fos antibodies. Specificity of the    
band-shifts was established by adding 200 fold excess of non-radioactive pcjun (-88/-28) 
self-probe (+comp). a IgG rabbit was used as isotype control. EMSA using pcjun (-88/-28) 
mAP-1 as a probe failed to bind c-Jun or ATF-2. Asterisks (*) indicate unspecific shifts. 
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Figure 7B: Increased DNA binding of c-Jun and ATF-2 upon AML1-ETO 
induction. 
EMSA using a bp -88 to bp -28 c-jun promoter oligonucleotide: pcjun (-88/-28), as 
described in Figure 7A. Increasing concentrations of non-radioactive pcjun (-88/-28)    
self-probe (25ng to 100ng) were added in order to slowly compete away the slower 
migrating shift composed of c-Jun and ATF-2. Asterisks (*) indicate unspecific shifts.  
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5.7 Interference with the JNK signaling pathway disrupts the 
functional properties of AML1-ETO 
In order to elucidate the functional importance of the JNK signaling pathway for 
AML1-ETO induced transactivation of the c-jun promoter, we investigated whether 
disruption of the JNK signaling pathway can interfere with the transactivation capacity of 
AML1-ETO on the c-jun promoter (Figure 8A).  
For that, we transiently transfected a proximal c-jun promoter construct                
(bp -79 to bp +170) into U937T/A-E and U937T cells, each grown with or without 
tetracycline and overexpressed JIP-1. JIP-1 is a scaffold protein which aggregates 
components of the JNK pathway to a functional signaling module.109 In overexpression 
studies, however, JIP-1 sequesters JNK from its nuclear targets,110 like c-Jun and ATF-2, 
and thus functions as an inhibitor of JNK regulated gene expression.111 Overexpression of 
JIP-1 in U937T/A-E cells after 36 hours of AML1-ETO induction, reduced transactivation 
capacity of AML1-ETO approximately 5 fold, from around 260 to 40 fold, which suggests 
that JNK might play a role in the stimulation of the c-jun promoter by AML1-ETO.  
Furthermore, we assessed whether the inhibition of JNK could revert the biological 
function of AML1-ETO. AML1-ETO induction for 3 days in U937 cells has been shown to 
induce proliferation arrest and apoptosis.88 We tried to block AML1-ETO induced 
apoptosis with cell-permeable JNK specific inhibitor peptides (JNK inh.).102 As revealed in 
AnnexinV assay, addition of these peptides to U937T/A-E cells after 72 hours of      
AML1-ETO induction reduced AML1-ETO induced apoptosis by around 30%, while 
addition of the HIV-TAT 48-57 negative control peptide (neg.co.) had no effect. No effect 
was seen for U937T/A-E cells grown in the presence of tetracycline or for the U937T 
control cell line (Figure 8B). 
These results underline the biological importance of the JNK signaling pathway for  
AML1-ETO induced apoptosis in U937 cells.  
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Figure 8A: Disruption of the JNK signaling pathway reduces the transactivation 
capacity of AML1-ETO on the c-jun promoter.  
After 12 hours of growth with tetracycline (+tet) or without tetracycline (-tet), U937T and 
U937T/A-E cells were transiently transfected with a c-jun promoter construct ranging from 
bp -79 to bp +170 (pcjun -79/+170) or the empty vector pGL2 and co-transfected with 
0.2µg of JIP-1. Cells were analyzed 24 hours post transfection. The normalized luciferase 
activity of each construct was arbitrarily defined as 1 fold promoter activity. The promoter 
activity in presence of AML1-ETO was presented in relation to it (fold promoter activity). 
Thus, effects of AML1-ETO on the empty vector plasmid (pGL2) could be more visible. 
Transfection data is shown as mean ± S.D. of 3 separate experiments.  
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Figure 8B: Interfering with the JNK signaling pathway reduces AML1-ETO 
induced apoptosis.  
Flow cytometry analysis of AnnexinV-FITC positive U937T/A-E and U937T cells grown 
for 72 hours in the presence or absence of tetracycline (+tet/-tet). 1µM of JNK specific 
inhibitor peptide (JNK inh.) or negative peptide control (neg. co.) was added to the cells at 
the time of induction. The upper panel shows overlays of counts of AnnexinV-FITC 
positive cells. Cells only are represented in blue, cells + JNK inhibitor in red and           
cells + negative control in green. In the lower panel, the average percentages of   
AnnexinV-FITC positive cells were blotted against each other. Data is shown as mean ± 
S.D. of three independent experiments using U937T/A-E cells and two independent 
experiments using U937T cells. 
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5.8 Indirect stimulation of the JNK signaling pathway by 
AML1-ETO: possible role for G-CSF and its receptor 
The question remains how AML1-ETO, which has no known kinase activity, 
induced the JNK signaling pathway. To investigate if AML1-ETO indirectly stimulated 
JNK signaling by inducing autocrine stimuli, supernatants of U937T/A-E or U937T cells 
were added onto wildtype U937 cells and whole cell lysates were analyzed by Western blot 
for phosphorylated JNK or c-Jun. Supernatants of U937T/A-E (Figure 9A, lanes 3 and 4) 
but not U937T cells (Figure 9A, lanes 1 and 2) increased phosphorylation of c-Jun and 
JNK in wildtype U937 cells, similar to what was observed for the cellular fraction of 
AML1-ETO expressing cells (Figure 6B).  
AML1-ETO has recently been shown to upregulate the expression of the 
granulocyte-colony stimulating factor (G-CSF) receptor,96 which can mediate Ras-
dependent activation of the JNK signaling pathway.112 Furthermore, in an ovarian cancer 
cell line, induction with G-CSF increases JNK signaling and c-Jun expression.101  
Therefore, we examined the expression of G-CSF and its receptor in U937T/A-E 
cells by real-time PCR and found that AML1-ETO induction increased the mRNA 
expression of G-CSF (Figure 9B, upper panel) and the G-CSF receptor (Figure 9B, lower 
panel) in the U937T/A-E cells after 24 hours of AML1-ETO induction. Furthermore, we 
found that priming of U937T/A-E cells after 48 hours of AML1-ETO induction with        
G-CSF further increased AML1-ETO induced phosphorylation of Thr183 and Tyr185 in 
JNK. This indicates that exogenous G-CSF enhanced the effect of AML1-ETO on JNK 
signaling (Figure 9C). G-CSF also slightly increased the phosphorylation of JNK in the 
U937T/A-E cells grown in the presence of tetracycline (U937T/A-E +tet) (Figure 9C), 
which might be due to the endogenous expression of the G-CSF receptor in U937 cells.113  
These results indicate that AML1-ETO might stimulate JNK signaling by inducing 
autoregulatory loops in U937 cells, which might involve G-CSF and its receptor. 
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Figure 9A: Indirect activation of the JNK signaling pathway by AML1-ETO. 
Western blot analysis for phosphorylated Ser63 in c-Jun: c-JunP (Ser63) and 
phosphorylated Thr183 and Tyr185 in JNK: JNKP (Thr183/Tyr185). Supernatants of 1x107 
U937T/A-E cells (S/N U937T/A-E) (lanes 3 and 4) and U937T cells (S/N U937T) (lanes 1 
and 2) were harvested 48 hours after growth in the absence of tetracycline and added to 
1x107 wildtype U937 cells for 15 or 30 minutes. Whole cell lysates were prepared and 
analyzed. Both blots were re-blotted for ß-tubulin. 
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Figure 9B: Upregulation of G-CSF and G-CSF receptor mRNA expression upon 
AML1-ETO (A-E) induction. 
Real-time PCR for G-CSF (upper panel) and G-CSF receptor (G-CSF-R) (lower panel) of 
U937T/A-E and U937T cells after different hours of tetracycline withdrawal (hrs -tet). 
Ratios for G-CSF/G6PD (upper panel) and G-CSF-R/G6PD (lower panel) are shown as 
fold upregulation compared to time point zero (+tet), which was set to 1 fold. Data is 
shown as mean ± S.D. of 3 different experiments. 
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Figure 9C: G-CSF increases AML1-ETO induced phosphorylation of JNK. 
Western blot for phosphorylated Thr183 and Tyr185 in JNK: JNKP (Thr183/Tyr185), 
detecting p46 and p54 isoforms of JNK. U937T/A-E cells were grown for 48 hours in the 
absence of tetracycline (48 hrs -tet) or in the presence of tetracycline (48 hrs +tet) and 
stimulated with 10µM or 100µM G-CSF for 15 or 30 minutes. Blots were stripped and 
reblotted for ß-tubulin as loading control. 
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Figure 10: Model for regulation of c-Jun expression by AML1-ETO.  
AML1-ETO induces c-Jun expression in an indirect manner. AML1-ETO induces the 
expression of a humoral factor, for example G-CSF, which in turn leads to G-CSF receptor 
(G-CSF-R) mediated stimulation of the JNK signaling pathway. JNK signaling connects 
AML1-ETO to the proximal AP-1 site of the c-jun promoter, at which pre-bound c-Jun and 
ATF-2 are phosphorylated by JNK. Phosphorylated c-Jun and ATF-2 stimulate c-jun 
promoter activity and c-Jun expression. 
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 6. DISCUSSION 
Approximately 40% of AML is associated with the translocations t(8;21), t(15;17), 
inv(16) or t(9;11), encoding for the AML1-ETO, PML-RARa, CBFß-SMMHC, or      
MLL-AF9 fusion proteins, respectively.51 Despite the diversity of the involved fusion 
partners, these AML-associated chimeric proteins deregulate their target genes through 
common mechanisms.114 We suggest that these AML fusion proteins might also affect 
common targets and demonstrate in the present study that proto-oncogene c-jun was a 
frequently upregulated target gene (Figure 1).  
In the case of t(8;21), we identified that AML1-ETO, by employing an indirect 
mechanism including the JNK signaling pathway, upregulated c-Jun expression through the 
proximal AP-1 site. Furthermore, stimulation of c-jun expression was an acquired function 
of the AML1-ETO chimera independent of wildtype AML1 (Figure 4B).  
AML1-ETO can directly interfere with wildtype AML1 dependent transactivation 
in a dominant negative manner by either binding to AML1 consensus sites via the retained 
DNA binding domain,62,115 or by physically interacting with transcription factors instead of 
AML1 on their target gene promoters.82-84 Differential display analysis has, however, 
revealed that the majority of AML1-ETO target genes are independent of wildtype 
AML1,97 which suggests that they might be regulated in an indirect manner. The c-jun 
promoter does not contain AML1 consensus sites and in addition, we found that wildtype 
AML1 had no effect on c-jun promoter activity (Figure 4B). Furthermore, AML1-ETO 
could not bind to the proximal AP-1 site (Figure 5), which was mapped to be the      
AML1-ETO responsive site (Figures 4C+D).  
Physical interaction between c-Jun and AML1 has been reported via the runt 
domain of AML1,116 which is retained in AML1-ETO. This suggests that prebound c-Jun 
might also interact with AML1-ETO and tether AML1-ETO to the promoter.  
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However, we could not find such interaction between prebound c-Jun and     
AML1-ETO at the level of the c-jun promoter (data not shown). These findings imply that 
regulation of the c-jun promoter by AML1-ETO is indirect.  
Previous studies have indicated that specific signaling events might be important for 
the functional properties of AML1-ETO. Transformation capacities of AML1-ETO in 
NIH3T3 cells have been associated with elevated levels of phosphorylated Ser63 in c-Jun.49 
Also wildtype ETO requires H-Ras for transformation of 3T3 fibroblast cells.117 Therefore, 
pathways like the JNK pathway, which are both ras and c-Jun dependent, are candidate 
mechanisms for AML1-ETO dependent signaling.  
Unlike the leukemic fusion protein BCR-ABL, AML1-ETO has no known intrinsic 
kinase activity on its own, thus it appears more likely that it interferes with such signaling 
pathways in a rather indirect manner. ETO can interact with the regulatory subunit of type 
II cyclic AMP-dependent protein kinase via the NHR3 domain which is retained in   
AML1-ETO.118 Thus, one possible mode of action might be that AML1-ETO upregulates 
the activity of a kinase, or downregulates the activity of a kinase phosphatase by physical 
binding. An alternative possibility, which we have found to be more likely, is that      
AML1-ETO upregulates the expression of a cytoplasmic factor, which activates receptor 
mediated JNK signaling. A candidate factor for this is the hematopoietic growth factor     
G-CSF (Figure 9).  
It has previously been shown that primary AML blast cells can produce and respond 
to their own growth factors, like G-CSF, GM-CSF or IL1b,119,120 which allow them to grow 
autonomously.119 One group found that exogenous G-CSF results in differentiation of 
t(8;21) positive cells121 and cell lines,122 and they associate G-CSF induced differentiation 
with activation of the STAT signaling pathway.122 Stimulation of the JNK signaling 
pathway123 and c-Jun expression101 upon G-CSF administration is, however, associated 
with G-CSF induced growth stimulation.124,125  There is also evidence that AML1-ETO 
might play a role in proliferation upon G-CSF. AML1-ETO blocks G-CSF induced 
differentiation of IL-3 dependent cell lines and leads to G-CSF dependent proliferation.87  
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Furthermore, AML1-ETO promotes the expansion and self-renewal capacities of 
human hemopoietic stem cells.89 The mechanism is currently unknown, but an involvement 
of AML1-ETO in G1-to S-phase progression is discussed, as wildtype AML1 has shown to 
inhibit cell cycle progression.126 Also c-Jun has been implicated in G1-to S-phase 
progression and cell proliferation by negatively regulating tumor suppressors and cell cycle 
regulators.127  
We suggest that AML1-ETO and c-Jun might share additional functional properties, 
as c-Jun activation was also involved in the pro-apoptotic function of AML1-ETO in U937 
cells (Figure 8B). As described in this study, however, inhibition of the JNK signaling 
pathway in U937 cells reduced apoptosis only by about 30%, suggesting additional factors 
within AML1-ETO induced apoptosis (Figure 8B).  
This notion is further supported by our findings that AML1-ETO and c-jun mRNA 
expression levels correlated in primary t(8;21) positive cells and the fluctuating mRNA 
expression levels of AML1-ETO were responsible for the variability in c-jun expression 
(Figure 2). The biological relevance of the low levels of c-jun and AML1-ETO expression 
in some of the t(8;21) positive samples is unknown. A follow-up study on the expression 
levels of AML1-ETO and c-jun might give important insights whether patients with low 
levels of AML1-ETO and c-jun reach complete remission more rapidly. 
By assuming that upregulated c-Jun expression is important for proliferation or 
transformation properties of leukemic blast cells, as reported in leukemic translocations in 
CML,44,45,47  disruption of the c-Jun regulating JNK pathway might have therapeutic benefit. 
Inhibition of JNK has therapeutic potential in inflammatory diseases like rheumatoid 
arthritis128 or diabetes.102 t(8;21) expressing Kasumi-1 and SKNO cell lines are unique 
among a panel of myeloid cell lines that undergo apoptosis in response to dexamethasone 
treatment.129 Dexamethasone, a glucocorticoid with anti-inflammatory actions, reduces     
c-jun mRNA levels via the glucocorticoid receptor by inhibiting transactivation via the 
proximal and distal AP-1 sites of the c-jun promoter.11 This indicates that downregulation 
of c-Jun expression might be advantageous. 
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Alternatively, proliferation capacity in leukemic cells might be beneficial during 
standard chemotherapy of AML, as it increases sensitivity to S-phase specific cytotoxic 
agents such as cytosine arabinoside (AraC). One group investigated the proliferative 
activity in blast cells of various prognostic subgroups and found that blast cells from 
patients in the favorable subgroup including t(8;21), t(15;17) or inv(16), showed higher 
proliferative activity compared to the intermediate or unfavorable group.130 Intriguingly, we 
found high levels of c-jun expression in AML patient cells with translocations associated 
with good response to AraC, in t(8;21), t(15;17) or inv(16), whereas c-jun expression was 
low in t(11q23/MLL) positive patient samples, which are associated with bad prognosis.131 
The good prognosis subgroups are also more likely to produce endogenous G-CSF,       
GM-CSF or IL3.130 In accordance with this data we found that AML1-ETO upregulated the 
expression of G-CSF (Figure 9B, upper panel). 
Besides, we found that also t(15;17) positive acute promyelocytic leukemia (APL) 
patient samples have high levels of c-jun mRNA in comparison to normal bone marrow 
cells. Interestingly, t(15;17) positive patient cells contain high levels of G-CSF receptor and 
proliferate upon G-CSF priming, which increases their vulnerability to cell-cycle specific 
drugs.132 Increased endogenous G-CSF during differentiation therapy with ATRA results in 
proliferation,133 and ATRA treatment leads to increased AP-1 activity.134 These findings 
suggest that G-CSF, AP-1 activity and increased cell proliferation might also be important 
features in APL.  
In summary, our results indicate that high expression levels of proto-oncogene c-jun 
are a common feature amongst “good prognosis” AML-associated translocations. In the 
case of the translocation t(8;21), AML1-ETO upregulated c-Jun expression and activity in 
patient cells and cell lines by positively autoregulating c-Jun expression through the 
proximal AP-1 site of the c-jun promoter. c-Jun regulation was indirect via the JNK 
signaling pathway that in turn might be indirectly stimulated by positive autoregulatory 
loops which might involve G-CSF (Figure 10).  
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We propose that the identification of common targets and mechanisms amongst 
“good prognosis” AML-associated translocations might provide valuable knowledge for 
improving the therapeutic outcome of other AMLs. 
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7. SUMMARY 
Overexpression of proto-oncogene c-jun and constitutive activation of the Jun NH2-
terminal kinase (JNK) signaling pathway have been implicated in the leukemic 
transformation process. However, c-jun expression has not been investigated in acute 
myeloid leukemia (AML) cells containing the most common chromosomal translocations. 
t(8;21) is one of the most common AML-associated translocation and results in the   
AML1-ETO fusion protein. Overexpression of AML1-ETO in NIH3T3 cells leads to 
increased phosphorylation of Ser63 in c-Jun, which is generally JNK dependent. The role 
of the JNK signaling pathway for the functional properties of AML1-ETO is, however, 
unknown.  
In the present study we found high expression levels of c-jun mRNA in t(8;21), 
t(15;17) or inv(16) positive patient cells by microarray analysis. Within t(8;21) positive 
patient samples, there was a correlation between AML1-ETO and c-jun mRNA expression 
levels. In myeloid U937 cells, c-jun mRNA and c-Jun protein expression levels increased 
upon induction of AML1-ETO. AML1-ETO transactivated the human c-jun promoter 
through the proximal AP-1 site via activating the JNK signaling pathway. JNK targets       
c-Jun and ATF-2, which also bind to the proximal AP-1 site in U937 cells, were also 
phosphorylated upon AML1-ETO induction. Furthermore, AML1-ETO induction increased 
the DNA binding capacity of c-Jun and ATF-2 to the proximal AP-1 site of the c-jun 
promoter, which might result in their enhanced transactivation capacities.  
Interference with JNK and c-Jun activation by using JIP-1 or a JNK inhibitor 
reduced the transactivation capacity of AML1-ETO on the c-jun promoter and the pro-
apoptotic function of AML1-ETO in U937 cells. AML1-ETO seems to activate the JNK 
signaling pathway by inducing the expression of a cytoplasmic factor, possibly G-CSF, 
because supernatant of AML1-ETO expressing cells was sufficient to induce 
phosphorylation of JNK and c-Jun in wildtype U937 cells.  
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This data demonstrates a novel mechanism of how AML1-ETO might exert positive 
effects on target gene expression and identifies the proto-oncogene c-jun as a common 
target gene in AML patient cells.  
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8. ZUSAMMENFASSUNG 
Überexpression des Proto-Onkogens c-jun und konstitutive Aktivierung des         
Jun NH2-terminalen Kinase (JNK)-Signaltransduktionsweges sind wichtig für die 
leukämische Transformation in der Chronischen Myeloischen Leukämie. Die Expression 
von c-jun bei Akuter Myeloischer Leukämie (AML) mit den häufigsten reziproken 
Translokationen ist jedoch unbekannt. Bei einer der häufigsten AML Translokation t(8;21) 
wurde in Fibroblastenzellen gezeigt, daß das AML1-ETO-Fusionsgen die Phosphorylierung 
des Serin 63 in c-Jun erhöht. Die Rolle des JNK-Signalweges, der c-Jun am Serin 63 
phosphorylieren kann, für die Funktion von AML1-ETO wurde bisher jedoch nicht 
untersucht. Weiterhin kann aktiviertes c-Jun durch eine positive Rückkoppelungsschleife 
über den c-jun Promotor zur Erhöhung der c-Jun Expression führen. 
In der vorliegenden Arbeit konnten wir zeigen, daß AML Patientenzellen mit den 
häufigen Translokationen: t(8;21), t(15;17) oder inv(16) mehr c-jun mRNA besitzen im 
Vergleich zu Knochenmarkszellen gesunder Probanden. Weiterhin fanden wir eine hohe 
Korrelation zwischen der AML1-ETO und der c-jun mRNA bei t(8;21) positiven 
Patientenzellen. Induktion von AML1-ETO in der myeloischen U937 Zellinie erhöhte 
sowohl c-jun mRNA als auch c-Jun Proteinexpression. Damit konnten wir zeigen, daß 
AML1-ETO die Erhöhung der c-jun Expression bewirkt. Wir untersuchten den 
molekularen Mechanismus in U937 Zellen mittels transienter Transfektionen und fanden, 
daß AML1-ETO den c-jun Promotor durch die proximale AP-1 Seite transaktiviert. Diese 
Transaktivierung erfolgte indirekt über Aktivierung des JNK-Signaltransduktionsweges 
durch AML1-ETO. AML1-ETO-Induktion führte auch zur Phosphorylierung der         
JNK-Zielproteine c-Jun und ATF-2. Diese konnten im Gelretardierungsassay an die 
proximale AP-1 Seite des c-jun Promotors binden und wurden durch AML1-ETO-
Induktion in ihrer Bindungsfähigkeit verstärkt. Deshalb nehmen wir an, daß die 
Transaktivierungskapazität des c-jun Promotors durch AML1-ETO über die Aktivierung 
des JNK-Signalweges läuft.  
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Interferenz mit der Aktivierung von JNK und c-Jun mittels JIP-1 oder eines JNK 
Inhibitors konnte die Transaktivierung des c-jun Promotors durch AML1-ETO und auch 
die pro-apoptotische Funktion von AML1-ETO in U937 Zellen reduzieren. Da AML1-ETO 
keine Kinasefunktion besitzt, stellt sich jedoch die Frage, wie AML1-ETO den             
JNK-Signalweg beeinflussen kann. Wir konnten zeigen, daß Überstände AML1-ETO 
exprimierender U937 Zellen ausreichend sind für die Phosphorylierung von JNK und        
c-Jun. Dies führte zu der Annahme, daß AML1-ETO die Expression eines 
cytoplasmatischen Faktors erhöht, der wiederum den JNK-Signalweg beeinflußt. Dieser 
Faktor könnte G-CSF sein, da wir zeigen konnten, daß die Induktion von AML1-ETO in 
U937 Zellen die Expression von G-CSF und des G-CSF-Rezeptors erhöht und exogene 
Stimulation AML1-ETO exprimierender U937 Zellen mit G-CSF die Phosphorylierung von 
JNK erhöht.  
Die Induzierung positiver autoregulierender Loops durch AML1-ETO stellt einen 
neuen molekularen Mechanismus dar, wie AML1-ETO die transkriptionelle Aktivität 
seiner Zielgene positiv beeinflussen könnte. Weiter zeigen wir, daß das Proto-Onkogen     
c-jun in AML Patientenzellen mit reziproken Translokationen häufig überexprimiert ist. 
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